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CHAPTER I 
INTRODUCTION 
Introduction 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the 
production of auto-antibodies against self-antigens such as double-stranded DNA and 
phospholipids.  Clinical complications of SLE include end-organ diseases such as 
glomerulonephritis, infection, vasculitis, arthritis, skin disorders, and neurological disease.  
Causes of SLE mortality can be clustered into two main groups:  early mortality and late 
mortality (24, 61, 214).  The early mortality group includes glomerulonephritis, infection and 
neurological disease, whereas the late mortality group is mainly composed of cardiovascular 
disease (CVD).  Management of SLE complications has improved over the last several decades, 
causing a shift in mortality burden from early causes to late causes.   
CVD represents a large component of late disease burden in SLE patients (95).  In one 
study, nearly 40% of SLE patients were found to have carotid atherosclerotic plaques as 
compared to 15% of matched control subjects (181).  Another study showed that 31% of lupus 
patients had coronary artery calcification whereas only 9% of controls showed calcification 
(119).   The overall risk of CVD in females with lupus is five-fold greater than that of control 
subjects and this risk can be fifty times greater in some age groups (24, 119). 
 Although it is clear that SLE patients suffer disproportionately from CVD, the causes of 
this disparity have not been elucidated.  Various studies have shown a higher prevalence of 
traditional CVD risk factors such as hyperlipidemia or hypertension and non-traditional, SLE-
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specific risk factors such as autoantibody production or corticosteroid therapy (24).  One of these 
traditional risk factors, insulin resistance (IR), has higher prevalence in the SLE population (116) 
and may contribute to the high CVD burden in these patients.  IR has been associated with CVD 
risk in many studies (168, 172, 241) and the contribution of insulin resistance to atherosclerosis 
in the context of SLE merits further study. 
Although IR is increased in prevalence in the SLE population, the absolute number of IR-
afflicted individuals in the general population is exponentially higher.  This IR epidemic largely 
results from the increasing numbers of obese and overweight individuals in the developed world.  
The pathogenesis of many obesity comorbidities, including IR, is heavily influenced by systemic 
and tissue-specific inflammation.  This inflammation arises from interactions between the 
metabolic and immune systems, and white adipose tissue (WAT) has emerged as a key mediator 
of this interaction.  WAT, classically described as an inert energy storage depot, has recently 
been shown to play an active role in both metabolic homeostasis and immunity.  These 
capabilities are conferred by the ability of adipocytes to secrete more than seventy-five 
adipokines (230), which include a variety of chemokines, cytokines and hormones that can affect 
appetite, recruit leukocytes to WAT, and instigate systemic metabolic disruption (149, 179, 195).  
The recruited T cells, B cells and macrophages work in tandem with adipocytes to give rise to 
the metabolic syndrome. 
Recent findings have provided circumstantial evidence that obesity-related IR and SLE-
related IR share common pathogenic mechanisms.  Although the role of the adaptive immune 
system—specifically auto-antibody production—has long been known to be involved in the 
development of SLE, B cells have only recently been shown to act as central regulators of IR 
(224).  Specifically, B cells produced pathogenic IgG antibodies in the context of obesity which 
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are sufficient to confer insulin resistance in passively immunized recipient mice.  Therefore, B 
lymphocytes comprise a potential link between the pathogenesis of IR in SLE and obesity.  
There are limited data regarding metabolic syndrome in mouse models of SLE.  In the 
only other study of metabolic syndrome in an SLE model of which we are aware, Ryan et al. 
(185) have shown that the lupus-prone (NZB/W)F1 strain has increased adiposity, increased 
macrophage infiltration into adipose tissue, and increased glucose intolerance, but the 
contributions of the adaptive immune system to this metabolic phenotype were not examined.  
Therefore, the role of lymphocytes in the pathogenesis of insulin resistance in the context of SLE 
is not known and merits further study.  Furthermore, there are no reports on metabolic syndrome 
in other mouse models of SLE.   
 Chapter two of this thesis describes efforts to characterize the development of glucose 
homeostasis in the lupus-prone B6.SLE.1.2.3 strain of mice.  We show that B6.SLE mice have 
significantly worsened glucose tolerance and adipose tissue insulin resistance than B6 controls.  
This B6.SLE glucose intolerance occurs in the presence of a diabetogenic B cell environment 
which is characterized by the presence of an increased number of IgG-producing B cells and IgG 
depositions in the white adipose tissue as well as higher levels of circulating IgG.  Most 
interestingly, this strain of mice develops glucose intolerance and adipose tissue insulin 
resistance in an adiposity-independent manner, indicating that this strain may be a valid model 
for insulin resistance in the SLE patient population.  These studies provide data that elucidate the 
pathogenesis of insulin resistance in SLE patients and may provide greater insight into the 
development of insulin resistance in the obese population.  
 Chapter three shows that high-fat diet feeding does not significantly worsen 
glomerulonephritis or kidney function in B6.SLE mice.  Although this finding is in conflict with 
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earlier studies of SLE models, it is possible that changes in study design could reveal dietary 
factors that exacerbate or ameliorate disease in the B6.SLE mouse model.  Chapter four 
compares our results to those of other studies in SLE model models and SLE patients and 
proposes a mechanism for the pathogenesis of glucose intolerance and insulin resistance in the 
B6.SLE mouse model. 
Systemic Lupus Erythematosus 
 
Early History of Systemic Lupus Erythematosus 
 The term “lupus” dates to the 10th century A.D. and referenced the similarity of the 
cutaneous lesions to wolf bites (118, 192).  The diagnosis of lupus was refined over subsequent 
centuries until Laurent Biett and Louis Cazenave generated the term “lupus erythematosus” in 
the early 1800s and subdivided the condition into three subtypes distinguishable by the nature of 
the cutaneous lesions that were present: tubercular lupus, ulcerative lupus and hypertrophic lupus 
(216). The diagnosis of lupus erythematosus was specifically reserved for the cutaneous 
manifestations of the disease until Moriz Kaposi described concomitant visceral complications of 
lupus erythematosus in an 1872 article (192).  He noted that lupus patients were often found to 
have lymphadenopathy, joint swelling and pain, and anemia. His reports set the path for a more 
holistic understanding of the symptoms of the disease.  Kaposi’s writings, along with a series of 
lupus case reports written by Sir William Osler (154) helped to popularize the concept of lupus 
erythematosus as a systemic disease involving diffuse organ systems. 
 The first conclusive evidence that immunoglobulins were involved in the pathogenesis of 
SLE was gathered by Malcom Hargraves in 1948, who found that SLE patient serum could cause 
granulocytes—then named lupus erythematosus cells, or LE cells—to react with the nuclei of 
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bone marrow cells in normal patients (118).   The target of the serum factor eliciting this LE cell 
response was identified as nuclear material by Miescher and Fauconnet who found that 
adsorption of SLE patient serum with nuclear lysates prevented the LE cell cytotoxic response 
(129).  This line of research led George Friou to discover in 1958 that the LE factor was 
immunoglobulin and that one of its targets was the DNA:Histone complex (66, 67).  Subsequent 
studies by other research groups showed that SLE patients had antibodies that are specific for a 
wide variety of self antigens.  The finding that antibodies play a pivotal role in the pathogenesis 
of SLE paved the way for the hallmark screening test for lupus, the anti-nuclear (ANA) antibody 
test, a screen for  autoantibodies including anti-dsDNA, anti-histone, anti-Ro, anti-Sm, anti-
cardiolipin and anti-C1q (171).  Furthermore, the findings of Hargraves, Friou, Miescher, 
Fauconnet and other research groups provided critical early cues regarding the pathogenesis of 
SLE and initiated the modern era in the field of SLE. 
Modern Understanding of the Pathogenesis of SLE 
SLE is now recognized as systemic disease in which the immune system produces auto-
antibodies against various tissue antigens.  These antibodies give rise to an inflammatory cascade 
involving the complement system, innate immune cells and T cells.  As recognized by Osler and 
Kaposi, SLE can manifest itself in a variety of organ systems including the kidneys, the liver, the 
integumentary system, the musculoskeletal system, the cardiovascular system and the central 
nervous system.  Each of these manifestations share common underlying mechanisms in which 
antibodies cause dysfunction and damage directly or indirectly through engagement of the innate 
and adaptive immune systems.   
 One of the most common manifestations of SLE is lupus nephritis.  Nephritis can arise 
when antibody:nuclear protein complexes deposit on the glomerular basement membrane and 
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cause a type III hypersensitivity reaction (171).  These immune complexes elicit activation of the 
complement cascade—mainly via the classical pathway—which can cause direct damage to the 
nephron through membrane attack complexes and indirectly through recruitment of granulocytes, 
NK cells and macrophages to the basement membrane.  Additionally, autoantibodies against 
nuclear antigens like dsDNA and chromatin can cross-react with kidney antigens causing 
activation of the complement cascade and engagement of the innate immune system via the Fc 
receptor (13).   These mechanisms are broadly applicable to other tissues targeted in SLE.  
Less commonly, antibodies can have direct effects by acting as ligands for cell surface 
receptors.  An example of this phenomenon is neuropsychiatric lupus secondary to 
autoantibodies against the NMDA receptor.  These antibodies can function as antagonists or 
agonists of the NMDA receptor,  eliciting depression, cognitive impairment and/or psychosis 
(105).  Similarly, antibodies against insulin receptors can act as agonists of the insulin receptor, 
causing severe hypoglycemia, or antagonists, causing a subtype of insulin resistance classified as 
type B insulin resistance (158). 
 The production of autoantibodies in SLE depends on the failure of several checkpoints 
that normally protect against autoimmunity.  Firstly, clearance of apoptotic material in lupus 
patients and mouse models of lupus has been shown to be impaired, which permits exposure of 
nuclear antigens to the immune system (146).  Secondly, several major histocompatibility 
regions, including HLA-A1, HLA-DR2 and HLA-DR3 are associated with  lupus and may 
contribute to more efficient presentation of self-antigens (193).  Negative selection of 
autoreactive B cells can also be impaired in the setting of lupus.  Autoreactive B cells can be 
eliminated at several checkpoints: receptor editing, anergy, clonal deletion, and light chain 
editing in pre-B cells and immature B cells (17).  Overactive light chain editing has been 
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observed in humans and mouse models of lupus and has been associated with the production of 
autoreactive B cells (17, 113).  Furthermore, the over- or under-expression of various cytokines 
such as B cell activating factor (BAFF) can contribute to survival of autoreactive B cells (35, 
190).  Finally, mutations in several intracellular proteins and co-receptors related to negative 
selection can allow autoreactive B cells to mature and produce auto-antibodies that contribute to 
SLE pathogenesis.  For example, the expression of Ly108.2 isoform of the Ly108 co-receptor 
has been shown to be carried in the lupus susceptibility region of a mouse model of SLE and 
contributes to the survival of autoreactive B cells through interference with the apoptotic 
pathway and altered receptor editing  (218). 
 Dysfunction has also been observed in T cells from SLE patients and mouse models of 
SLE.  One of the most striking changes in the T cell population in the context of SLE is a 
deficiency in the ξ chain of the TCR complex.  In one study, SLE patients had reduced or absent 
ξ chain, a TCR complex component which bears phosphorylation sites necessary for transduction 
of TCR signals (111).    In a follow-up study, the same research group found that the ξ chain had 
been replaced by FcεRIγ chain, which is normally a component of the IgE receptor (55).  This 
substitution causes more intense signaling through the TCR, possibly through the utilization of 
Syk kinase in lieu of the canonical Zap-70 kinase (55).  
 The receptors, co-activator molecules, and intracellular machinery necessary for 
activation of T cells reside in lipid rafts.  Lipid rafts in SLE patients have been shown to vary in 
composition and location, and appear to be primed to respond to stimulus through the TCR.  In 
one study (92)  SLE T cells were shown to have increased CD45 and activated LCK occupancy 
in lipid rafts and accelerated recruitment of the lipid raft to the immunological synapse.  
Furthermore, the expression of c-Cbl, a ubiquitin ligase involved in the degradation of LCK, was 
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shown to be reduced in SLE T cells, providing a potential mechanism for the deranged LCK 
activity in SLE lipid rafts. 
 Co-stimulators and adhesion molecules involved in the activation, migration or 
suppression have been shown to be altered on the T cells of SLE-inflicted individuals.  For 
example, the induction of CTLA-4 is impaired in activated T cells from SLE patients (112)  and 
polymorphisms in the CTLA-4 gene are associated with SLE (213).  Since this molecule serves 
to dampen the activity of activated T cells, its deficiency could contribute to the hyper-
responsiveness of T cells in the context of SLE and serves as a potential drug target (130).  The 
CD40L costimulatory molecule is expressed on T cells and activates B cells to produce 
immunoglobulins by signaling through CD40.  CD40L expression has been shown to be 
increased in resting and activated T cells in SLE patients (49, 103).  Finally, the expression of 
adhesion molecules that facilitate the migration of pathogenic T cells has also been shown to be 
increased in SLE patients.  In one study, the severity of SLE symptoms was shown to correlate 
with the level of CD44 expression on patient T cells (59).  CD44 is a lipid-raft resident protein 
that is important for the migration of T cells into inflamed tissue. 
 IL-2 is, a cytokine expressed by T cells, serves in an autocrine fashion to maintain 
activation and proliferation.  Gene expression for the receptor and the cytokine is upregulated in 
response to ligation of the TCR.  IL-2 production is impaired in activated T cells from SLE 
patients (45).  Although lower IL-2 production would be expected to reduce the immune 
response, IL-2 deficient mice have been shown to develop autoimmune disease (187).  This 
paradoxical response could be explained by the absolute necessity of IL-2 for proper T 
regulatory cell development (150).  Deficiencies in the T regulatory cell population could 
counteract the effects of impaired T cell proliferation and activity. 
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 Subpopulations of T lymphocytes may protect against or exacerbate SLE.  As described 
above, T regulatory cells protect against excessive inflammation and reactivity against self-
antigens. T regulatory cells have been shown to be impaired in SLE patients and mouse models 
of SLE.  For example numbers and functions of T regulatory cells have been shown to be 
reduced in the setting of SLE (18, 115, 145, 157).   
 Th17 cells are a pro-inflammatory subset of CD4+ T cells which have been linked to the 
pathogenesis of several autoimmune diseases including rheumatoid arthritis, Crohn’s disease and 
SLE.  As indicated by their name, Th17 cells secrete IL-17 which can contribute to the activation 
and survival of pathogenic leukocytes (71).  Circulating IL-17 has been shown to be increased in 
SLE patient serum (228, 229) and Th17 cells have been shown to infiltrate the kidneys in the 
setting of lupus nephritis in both humans and mouse models (7, 237). 
Mouse Models of SLE 
 The NZB/W F1 mouse model of SLE is one of the oldest and most widely used models 
of spontaneous SLE.  In this model, lupus prone mice are generated through the mating of New 
Zealand Black mice with New Zealand White mice.  The F1 generation of this cross has a fully-
penetrant phenotype characterized by the production of autoreactive IgG and glomerulonephritis 
(160).  Many other lupus-susceptible strains have been generated from the NZB/W F1 strain 
through backcrossing with parental mice.  One of these strains—the NZM2410 inbred strain—
became the basis of extensive genetic testing for the susceptibility regions that predispose this 
family of SLE mouse models to the production of autoantibodies.  In a study published in 1994, 
Morel et. al backcrossed NZM2410 mice on the C57BL/6 background and used genetic interval 
mapping to identify regions that created susceptibility for glomerulonephritis (139).  These 
regions, named Sle1, Sle2, Sle3, and H-2 are mapped to chromosomes 1, 4, 7 and 17, 
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respectively.  In a later study, the same group used microsatellite marker mapping to backcross 
the Sle1, Sle2, Sle3, and H-2 lupus susceptibility regions on to the C57BL/6 background to create 
the B6.Sle.1.2.3 strain, heretofore referred to as B6.SLE mice (141).  Subsequent genetic 
dissection of the susceptibility regions revealed the specific defects carried by each region 
(Figure 1).  Mice bearing the Sle1 susceptibility region lost tolerance to anti-chromatin 
antibodies, which was attributed to an increase in histone-reactive T cells (133).  Sle2 was shown 
to elicit a hyperactive B cell phenotype which extends and amplifies autoimmunity (134).  
Finally, mice bearing Sle3 were shown to have accumulation of activated CD4
+
 T cells, 
increased T cell proliferation in response to stimulation and reduced apopotosis (135). 
Collectively, these susceptibility regions confer a fully penetrant lupus phenotype characterized 
by the production of autoantibodies against nuclear antigens and fulminant glomerulonephritis.  
Although human females are more likely to develop lupus, B6.SLE show nearly equal 
Figure 1.   Genetic loci and their functions in B6.SLE mice.  Adapted from Morel et al. Laboratory 
Medicine. 339:335-339. 1996. 
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penetrance of glomerulonephritis between genders (139).  Additionally, Sle1 is syntenic with 
regions of human chromosome 1 that have been shown to be linked to development of SLE in 
humans (60). 
 Other spontaneous mouse models of SLE include the MRL/lpr and BXSB/Yaa strains.  
The MRL/lpr strain carries a defective Fas apoptosis signaling molecule which facilitates 
survival of autoreactive T cells during negative selection (124).  MRL/lpr are one of the only 
spontaneous models that develop arthritis and skin lesions (73), and may be particularly suited 
for the study of neuropsychiatric lupus (76).  The BXSB/Yaa strain carries lupus susceptibility 
genes on the y chromosome (the y-linked autoimmune accelerator) which were duplicated 
secondary to a translocation from the x chromosome (160, 164). This translocation predisposes 
male mice from this strain to developing a lupus-like phenotype consisting of the production of 
auto-antibodies againt nuclear antigens and immune-complex-mediated glomerulonephritis. 
The most commonly used model of inducible lupus is the pristane mouse model.  
Pristane, also known by its chemical name tetramethylpentadecane, is a hydrocarbon that was 
found to induce a lupus-like syndrome when injected intraperitoneally.  The lupus phenotype in 
these mice is characterized by the production of auto-antibodies against nuclear antigens, 
arthritis and serositis and glomerulonephritis secondary to the deposition of immune complex on 
the basement membrane (175, 191).   
Lupus Therapy 
When Osler published his widely cited series of case reports on suspected SLE patients at 
the turn of the 20
th
 century, the available therapy for SLE was rudimentary and mainly 
supportive (154).  This was summarized in his 1903 text, in which he wrote: 
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The very chronic cases [of SLE] with recurring colic for years 
may resist all measures.  Alterative courses of gray powder, with 
careful dieting, may be helpful.  With angioneurotic edema 
nitroglycerin in full doses may be tried…The chief danger is from 
the kidneys and in so frequently presenting this subject I have 
hoped to impress upon my colleagues the importance of 
recognizing this form of nephritis, and of taking early precautions 
to prevent its progress, against which I think protracted rest in bed 
and a milk diet are the best means at our disposal. 
The pharmacological armamentarium for SLE treatment has remained limited since those words 
were written by Osler 100 years ago.   Perhaps one of the largest advances in the treatment of 
SLE was the discovery and clinical utilization of corticosteroids in the first half of the 20
th
 
century, although corticosteroids weren’t approved for use in SLE by the FDA until 1955 (118). 
Additional major FDA-approved SLE drugs were aspirin (approved in 1948) and the anti-
malarial agent choloroquine (approved in 1955) (131).  Other immunosuppressants have been 
used off label in the treatment of SLE, including mycophenolate mofetil, cyclophosphamide, and 
rituximab (211).  However, many of these therapies—especially the immunosuppressants—carry 
significant side effects and may not be suitable for long-term treatment regimens.  Belimumab, a 
monoclonal antibody against soluble B cell activating factor was the next drug approved by the 
FDA in 201l, over 50 years after the approval of corticosteroids and choloroquine.  However 
belimumab was not tested in African Americans or in patients with lupus nephritis; therefore, its 
utility in the treatment of these large subsets of lupus patients is unknown.   
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Metabolic Syndrome 
Overview of Metabolic Syndrome and Inflammation 
The metabolic syndrome consists of several inter-related disorders, including the “deadly 
quartet” of truncal obesity, insulin resistance, hypertension, and dyslipidemia (8, 18).    Insulin 
resistance, a key component of type 2 diabetes mellitus (T2DM), is thought to be caused by 
chronic inflammatory processes involving complex interactions between cells of the metabolic 
and immune systems.  The link between inflammation and diabetes was first shown in the late 
19
th
 century when W. Ebstein treated his T2DM patients with large doses of aspirin, a non-
steroidal anti-inflammatory drug (46).   
More contemporary studies have yielded crucial information linking diabetes and 
inflammation.  Fat tissue has been shown to be a main focus of the chronic inflammation that 
gives rise to insulin resistance and T2DM.  Examination of fat tissue has revealed an 
accumulation of adipose tissue macrophages (ATMs) in obese mice (59), and blocking the 
accumulation of these cells attenuates insulin resistance (58).  ATMs have been shown to be key 
mediators of inflammation and insulin resistance in the setting of obesity (58, 59).  This field has 
focused on the opposing roles of pro-inflammatory classically-activated (M1) macrophages and 
anti-inflammatory alternatively-activated (M2) macrophages in adipose tissue inflammation.  
The development of M1 macrophages is induced by bacterial products such as LPS and the T-
helper type 1 (TH1) cytokine IFN-γ, whereas M2 macrophages are induced by T-helper type 2 
(TH2) cytokines such as IL-4 and IL-13 (37).  M1 macrophages produce proinflammatory 
mediators including TNFα, IL-6, IL-12, nitric oxide and reactive oxygen species and are thought 
to play a role in combating bacterial infections. Conversely, M2 macrophages produce the anti-
inflammatory cytokine IL-10 (3) and are thought to play  a role in tissue remodeling.  Insulin 
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resistance is ameliorated in both transgenic mice deficient in M1 ATMs and mice treated with 
pharmacological agents that shift ATMs to the M2 phenotype (17, 38).  Additionally, similar 
manipulations instigate M2 deviation in hepatic Kupffer cells and improve whole body insulin 
resistance. Both macrophages and adipocytes appear to serve as sources of the inflammatory 
cytokines TNFα and IL-6, which are abundant in the adipose tissue of obese individuals (60).   
More recent studies have implicated the adaptive immune system in the pathogenesis of 
insulin resistance.  CD8
+
 T cells exacerbate and T regulatory cells ameliorate insulin resistance 
in the context of obesity (62, 151, 225), and B cells have been shown to exacerbate insulin 
resistance through the production of pathogenic immunoglobulin (224). 
Several mechanisms of obesity-induced immunoactivation have been proposed.  The 
endoplasmic reticulum (ER) acts a sensor of metabolic stress which can promote the 
inflammatory state by influencing NFκB and JNK signaling (15, 40), and oxidative stress 
induces both insulin resistance and the secretion of pro-inflammatory cytokines in adipocytes 
(12, 51).  Additionally, members of the peroxisome-proliferator activated receptor (PPAR) 
family modulate immune system function by acting as sensors of fatty acids (44).  Interestingly, 
pattern recognition receptors on adipocytes, macrophages and dendritic cells appear to play a 
role in diet-induced inflammation (26, 45, 65).  Toll-like receptor 4 (TLR4), most commonly 
known as a sensor of bacterial lipopolysaccharide (LPS), has been shown to mediate the 
production of pro-inflammatory cytokines (45) and cyclooxygenase 2 (COX-2) (26) in response 
to saturated fatty acids.  COX-2 is a key component of the prostaglandin biosynthesis pathway 
and is the target of an important class of anti-inflammatory drugs.  Omega-3 polyunsaturated 
fatty acids (n-3 PUFAs) have been found to suppress the effects of saturated fatty acids by 
blocking TLR4-mediated activation of macrophages, dendritic cells, and adipocytes (26, 45, 65).  
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 The signals resulting from obesity-induced ER stress, oxidative stress, PPAR ligation, 
and TLR signaling contribute to a pro-inflammatory state in the affected cells, characterized by 
the secretion of inflammatory cytokines. These cytokines give rise to more inflammation within 
the adipose tissue, creating a “vicious cycle” of chronic inflammation.  These signals directly 
contribute to insulin resistance by acting on the JNK pathway ultimately causing the inactivation 
of insulin receptor substrate 1 (IRS-1) which is a key mediator of insulin receptor signaling (43, 
46).   
 Insulin sensitivity can also be affected through modulation of PPAR-gamma, a 
transcription factor that acts as a central regulator of adipocyte development and activity.  The 
thiazolidinedione class of drugs—including rosiglitazone and troglitazone—has been efficacious 
in the treatment of type 2 diabetes in humans and was thought to act as classical agonists of 
PPAR-gamma.  In turn, PPAR-gamma activity was hypothesized to exert its insulin-sensitizing 
effects by causing beneficial lipid storage in adipocytes (termed the “lipid steal” hypothesis) and 
by modulating the production of adipokines in adipocytes (207).  More recent studies have 
indicated that obesity-induced inflammatory stimuli upregulate Cdk5 activity, which in turn 
mediates phosphorylation of PPAR-gamma at its serine 273 residue.  This phosphorylation 
modulates the activity of PPAR-gamma, causing downstream effects which ultimately result in 
insulin resistance. Thiazolidinediones were found to prevent this phosphorylation, allowing 
PPAR-gamma to exert an adipocyte transcriptional program that protects against insulin 
resistance (36).  Although thiazolidinediones are thought to act primarily on adipocytes, studies 
by Benoist et al. showed that they also promote the expansion of T regulatory cells in the adipose 
tissue (40).  This expansion of immunosuppressive lymphocytes protects against obesity-induced 
inflammation and insulin resistance.  Interestingly, PPAR-gamma agonists have also been shown 
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to ameliorate autoimmune disease in mouse models, including the multiple sclerosis model 
experimental autoimmune encephalomyelitis (102).  
 An additional factor that has been shown to play an important role in glucose homeostasis 
is the intestinal microbiota.  The ground-breaking studies of Gordon et al.  showed that obese 
mice have a unique intestinal bacterial profile relative to lean controls and that these bacteria can 
confer weight gain and glucose intolerance when transferred into gnotobiotic mice (50).  These 
microbial changes were also shown to occur in humans.  Studies of twins showed that mono- and 
dizygotic twins shared a core component of bacterial species, but that an obese twin had a less 
diverse and significantly different array of bacterial species than their lean counterpart twin 
(212).   Furthermore, modulation of the microbiota with broad-spectrum antibiotics ameliorated 
glucose intolerance and insulin resistance in obese mice, perhaps by reducing levels of 
circulating LPS and inflammatory cytokines (30).  The microbiota has also been shown to 
modulate pathogenesis of autoimmune disease in several mouse models.  Rheumatoid arthritis-
prone K/BxN and Il1rn
-/-
 mice do not develop disease in germ free conditions, but the 
introduction of segmented filamentous species or Lactobacillus bifidus, respectively, were able 
to induce disease in these models (1, 235).  Similarly, the experimental autoimmune 
encephalomylelitis mouse model of multiple sclerosis develops less severe disease under sterile 
conditions.  Conversely, segmented filamentous bacteria exacerbate disease through modulation 
of IL-17 producing Th17 cells (107).  
Mouse Models of Metabolic Syndrome 
The most widely utilized genetic mouse models of obesity are the ob/ob and db/db 
strains.  The ob/ob strain resulted from a spontaneous mutation in a house mouse colony at the 
Jackson Laboratory and was published in a landmark article that described the discovery of some 
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“very plump young mice” during the summer of 1949 (89).  The ob/ob mice had rapid weight 
gain relative to their controls, ultimately achieving body weights over two times greater than 
their littermates.  Sixteen years later, the parental mice of the db/db strain were discovered in 
another mouse colony at the Jackson Laboratory (84).  The phenotype of this new strain was 
indistinguishable from that of ob/ob strain and both strains demonstrate rapid and uncontrolled 
weight gain and hyperglycemia.  The similarity of the phenotype was a source of curiosity for 
scientists in the obesity field and clues regarding the underlying mutations for each strain were 
provided by classic experiments completed by D.L. Coleman at the Jackson Laboratory (41). In 
his experiments, parabiosis was used to link the circulatory systems of ob/ob and db/db mice 
with each other and with control strains.    In his discussion, Coleman wrote: 
 
These observations provide further support for the conclusion that 
the obese [ob/ob] mouse has a functional satiety center and that it 
is capable of responding to satiety factor produced by normal as 
well as diabetes [db/db] partners. If these conclusions are correct, 
the identical obese-hyperglycemic syndromes produced by these 
two unrelated and separate genes would be explained. In one case, 
the target organ (satiety center) is defective while in the other the 
satiety factor is either not produced or is produced in insufficient 
quantities. Both mechanisms would cause over-eating and produce 
identical secondary changes in both obese and diabetes mice. 
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His conclusions aptly predicted the results of another landmark study by Zhang et. al conducted 
two decades later, in which the mutated gene from ob/ob was found to encode a secreted protein 
which later became known as leptin (243).  Two years later, the leptin receptor was identified 
and was implicated as the defective gene in db/db mice (206) .  Leptin has since been shown to 
be an adipocyte-secreted hormone that provides a satiety signal to receptors in the hypothalamic 
feeding center (65).  In db/db mice, the leptin receptor is mutated and cannot transduce the 
satiety signal to feeding center in the hypothalamus.  In contrast, ob/ob mice lack leptin and 
therefore cannot signal satiety to the hypothalamus.  Both mutations result in the uncontrolled 
eating and weight gain seen in db/db and ob/ob mice.  The obesity contributes to the severe 
insulin resistance and hyperglycemia seen in these models.   
 Another commonly-used model of mouse obesity is the diet-induced model (DIO).  In 
this model, obesity is induced by feeding mice a diet high in kilocalorie percentages from fats 
which is meant to replicate the modern Western diet.  The weight gain seen in these models is 
generally not as rapid or severe as seen as in ob/ob or db/db strains, but is perhaps more 
analogous to the amount of weight gain seen in humans eating a fatty diet.  However, DIO mice 
do develop insulin resistance and other components of the metabolic syndrome.  A chief 
advantage of this model—aside from its relatively greater clinical relevance—is the ability to 
induce obesity in any strain of mice needed for experiments. 
Immunity and Nutrition: Immunity in the Setting of Starvation and Malnutrition 
 Although malnutrition has long been associated with increased risk of infection, the 
immunological mechanisms behind these observations were not  described until Ranjit Chandra 
published a series of papers in the 1970s (31–34).  Dr. Chandra and others showed that protein-
energy malnourished (PEM) children had lymphoid tissue involution, impaired humoral and 
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cellular adaptive responses to antigens, and defective neutrophil function.   These deficiencies 
led to impaired primary response to infection and attenuated response to poliovirus and measles 
vaccines (31).  Studies from other groups showed that PEM rodents had reduced numbers of 
blood and bone marrow leukocytes, impaired leukocyte migration into areas of sterile 
inflammation and decreased LPS-stimulated production of TNF-α, IL-1β, and IL-6 of peripheral 
blood leukocytes (19, 51, 147).  Additionally, PEM rodents have higher mortality rates when 
challenged with influenza virus (178) and salmonella (159).  Specific changes in the lymphocyte 
compartment have also been observed in both PEM mice and humans.  Malnourished mice had 
significantly higher proportions of quiescent T cells in the blood and secondary lymphoid tissues 
than in well-nourished controls (232, 233).  Furthermore, T cells in PEM rats had a significantly 
reduced ability to synthesize and secrete IL-2 and Ifn-γ (126).  More recent studies have shown 
that PEM prevents maintenance and expansion of memory CD8+ T cells and memory B cells in 
mice (91, 121) and suppressed generation of effector T cells in malnourished children suffering 
from infection (152).  Collectively, these PEM-associated immune deficiencies inhibit host 
defense against pathogens and prevent the generation of immunological memory after primary 
infections and immunizations.  
 Similar results have been observed in patients suffering from anorexia nervosa.  There is 
a reduction in the numbers of circulating T cells in anorexic patients (120) and those that remain 
have lower Ifn-γ secretory capacity and reduced proliferation capacity (165).  Additionally, there 
is a marked decrease of CD8+ memory cells in anorexic patients (166) which is accompanied by 
deficiencies in delayed type hypersensitivity (Type IV hypersensitivity) response in the most 
severe cases of anorexia (161).  These results conflict with other studies which showed normal 
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generation of humoral and cellular immunity in anorectic patients (8, 75, 169), a discrepancy 
which may be explained by differences in patient group disease severity between studies. 
 Calorie restriction has been widely promoted as a way to increase longevity, but recent 
studies have called this into question.  Two parallel calorie restriction studies conducted at the 
National Institute of Aging (NIA) and the University of Wisconsin demonstrated the importance 
of macronutrient and micronutrient dietary content in modulation of aging (42, 125).   The 
University of Wisconsin study demonstrated increased longevity in rhesus monkeys fed 30% 
fewer calories from their respective baseline consumption versus controls fed the same diet ad 
libitum.  The NIA study, however, showed no difference in longevity between mice fed 30% 
fewer calories than baseline consumption and control monkeys who were fed 100% of their 
baseline caloric consumption.  The authors of the NIA study hypothesized that different dietary 
components between their study and the University of Wisconsin study accounted for the 
different study results.  Namely, the Wisconsin study utilized a diet with ten times higher sucrose 
content than that used in the NIA study, whereas the diet used in the NIA study contained a 
significant amount of anti-oxidant flavonoids and omega-3 fatty acids from fish oil.  Finally, all 
study monkeys were given supplementary vitamins and minerals whereas only the calorie 
restricted animals were given supplements in the Wisconsin studies.   
There has been limited study of immune function in the context of calorie restriction.  A 
six-month calorie restriction regimen in overweight humans increased the delayed-type 
hypersensitivity reaction and proliferation of T-cells in response to tuberculin and candida 
albicans antigens (2).  Calorie restriction has been shown to prevent T cell senescence in rhesus 
monkeys (128), although T cell function can be negatively impacted or unaffected if calorie 
restriction is initiated in juvenile monkeys or “elderly” monkeys, respectively  (127).  Studies in 
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mouse models showed that calorie restriction prevented age-related thymic involution and 
maintained T cell function and the T cell receptor repertoire (238).  Furthermore, calorie 
restriction ameliorates disease in rodent models of experimental autoimmune encephalitis and 
SLE partly through modulation of T cell and B cell numbers and functions (58, 68, 162, 202).  
Although changes in immune function have been observed in the context of calorie restriction, it 
is not clear whether these changes confer protection against infectious agents.  In a study of 
salmonella infection in mice, calorie restriction—but not protein energy malnutrition—reduced 
mortality in infected mice (159).  Calorie restriction also expedited recovery from Streptococcus 
zooepidemicus lung infection in mice (52), but increased mortality in a mouse model of 
polymicrobial peritonitis (203).  
Comparison of calorie restriction immune effects to those in protein energy malnutrition 
and anorexia highlights the importance of specific macro- and micronutrients to the development 
and maintenance of the immune system.  This contrast is especially apparent when comparing 
the effects of calorie restriction to protein energy malnutrition.  In calorie restriction 
experiments, the main intervention is to lower the overall caloric consumption while maintaining 
equivalent vitamin and mineral content.  In protein energy malnutrition studies, the experimental 
diet is specifically designed to contain fewer calories from protein but to contain the same 
amount of vitamins and minerals as the control diet.  However, in studies of humans suffering 
from PEM, it was difficult to extricate the effects of protein deficiency from that of micronutrient 
deficiency.  Although the majority of studies of malnutrition have focused on protein-calorie 
malnutrition, there is an increasing body of work which links immune function to specific 
micronutrients such as vitamin A.  A series of studies conducted in 1980s and 1990s, which 
showed that Vitamin A supplementation reduced mortality rates and hastened recovery in South 
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African children with measles (86) and reduced overall mortality in malnourished children (198).  
Although the mechanism behind this protective effect is not clear, it has been shown that vitamin 
A deficiency can disrupt the development and function of the innate and adaptive immune 
systems (137).  Mice fed a Vitamin-A-deficient diet have a significantly reduced ability to 
produce protective TH2-related IgG1 antibodies in response to helminth infection (27).  The 
deficiency in IgG1 production in Vitamin A-deficient mice is partly due to shift from TH2 
cytokine secretion (i.e. IL-4) to TH1 cytokine secretion in the helper T cell compartment (28, 29), 
a reduction of T helper cell numbers and a reduction in clonal expansion of B cells in response to 
antigen (197).  Vitamin A primarily exerts its effects through its retinoic acid (RA) metabolite 
and the retinoic acid receptor (RAR) nuclear hormone receptor. RA has been shown to facilitate 
the development of adaptive T regulatory cells in and inhibit the differentiation of TH17 cells 
within mucosal associated lymphoid tissue (12, 43, 48, 144, 201, 236).  A more recent study by 
Hall et al. revealed a more nuanced role for RA by showing that it was also necessary for the 
generation of the pro-inflammatory TH17 cell response to Toxoplasma gondii infection and OVA 
immunization in a RAR-dependent manner (79).  These findings contrast with previous studies 
which showed that it ameliorated mouse models of autoimmune disease through enhancement of 
the T regulatory cell suppressive response and regulation of the TH17 response.  This indicates 
that Vitamin A can either enhance or suppress inflammatory cell function depending on disease 
context.  Other vitamins have also been associated with the development of autoimmune disease.  
For instance,  Vitamin D has already been implicated in the pathogenesis of SLE and serum 
levels of this vitamin are reduced in SLE patient populations and negatively correlate with 
disease severity (177). 
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Immunity and Nutrition: Immunity in the Setting of Dietary Excess 
 The study of immune function in the context of dietary excess has been an area of intense 
study over the last two decades and the understanding of immunity in this setting is much more 
developed than in the setting of malnourishment. As described above, the adipose tissue has been 
a primary focus of studies in this field.  Once thought to be an inert lipid storage depot, 
adipocytes are now known to influence the activity of many other organ systems through 
secretion of chemokines, cytokines and hormones.  One of these affected systems—the immune 
system—has been an area of intense research within the diabetes field over the last decade.  
Although the relationship between inflammation and diabetes has been known since the late 
1800s, the modern era of investigation in this area began in 1993 when Spiegelman et al. showed 
that the pro-inflammatory cytokine TNF-α contributed to insulin resistance in the adipose tissue 
of obese rodents and humans (82).  The innate immune system was first implicated in obesity in 
2003 by Ferrante et al., who showed that adipose tissue macrophage accumulation was 
associated with TNF-α expression and insulin resistance (223).  Since 2003, several other 
leukocyte classes and subtypes have been shown to reside in adipose tissue and influence obesity 
and diabetes. T regulatory cells (62), M2 macrophages (153) and eosinophils (234) have been 
shown to be protective, whereas neutrophils (205), mast cells (74), M1 macrophages(153), B 
cells (224), TH17 cells (246), and CD8+ cells (151) exacerbate obesity and insulin resistance.  
 The rise in obesity rates in the United States have been accompanied by a rise in the 
prevalence in autoimmune disease, and several studies have offered clues regarding potential ties 
between these trends.  In one study, HFD-feeding exacerbated mouse models of multiple 
sclerosis and colitis in an TH17 cell dependent manner (226), but the mechanistic link between 
obesity and TH17 cell activity has not been elucidated.  One potential link is the satiety-signaling 
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hormone leptin.  This hormone is produced by adipocytes and serum levels increase as body fat 
increases.  Leptin’s primary role is to signal satiety through receptors in the hypothalamic 
feeding center, but recent studies have shown effects in the periphery, including in the immune 
system.  T cells express leptin receptor and TH17 cell differentiation is enhanced by addition of 
leptin to Naïve CD4
+
 T cell cultures (47).  Furthermore, leptin injections exacerbate disease in a 
mouse model of arthritis (47).  Leptin deficiency and neutralization protects against allograft 
rejection (138) and EAE (69, 182) through a reduction of the TH1 and TH17 cellular response.  
Additionally, leptin acts as a negative regulator of T regulatory cell development and function 
(163).  In humans, increased leptin levels have been observed in patients with psoriasis (220), 
rheumatoid arthritis (156) and lupus (70). 
The evolutionary advantage for increased suppressive T regulatory cell activity in the 
fasting (low leptin) state is not immediately apparent.  Since the generation of an immune 
response necessitates significant energy expenditure, it is possible that T regulatory cells 
contribute to energy conservation by immune system activity when food intake is low.  
Conversely, leptin may act as a signal to pro-inflammatory TH1 and TH17 cells that energy 
resources are sufficient to mount an immune response.  Mice lacking leptin or leptin receptor 
have impaired immune function and fasted wild-type mice have decreased delayed-type 
hypersensitivity response to antigens (69).  Addition of exogenous leptin is sufficient to restore 
immune function in fasted mice or leptin-deficient mice, which suggests that immune cells are 
directly affected by the lack of leptin and may not directly sense a lack of nutrients.    
Metabolic Syndrome, Insulin Resistance and Obesity in Lupus 
There have been several case reports describing insulin resistance in humans suffering 
from SLE.  Many of the earliest studies referenced an insulin resistance type b phenomenon in 
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which autoantibodies against the insulin receptor or free insulin impaired normal insulin 
signaling (63, 93).  One of the earliest cases of lupus-related type B insulin resistance was 
reported in 1981, in which a 22 year-old female who had recently been diagnosed with SLE was 
found to have hyperinsulinemia and diabetes that responded to corticosteroid treatment (221).  
Many other cases of lupus-related type B insulin resistance have been published in the literature 
(11, 15, 72, 97, 109, 136, 155, 158, 170).   Collectively, these case studies described patients that 
presented with hyperinsulinemia accompanied by deranged glucose homeostasis. In two thirds of  
patients, insulin receptor antibodies can block insulin binding, resulting in hyperglycemia (25).  
In the remaining third, the insulin receptor antibodies can potentiate the insulin response, causing 
episodes of hypoglycemia.  Patients with type B insulin resistance can vacillate between 
hyperglycemia and hypoglycemia during the course of the disease, but blood glucose can be 
effectively managed using conventional SLE therapies such as corticosteroids and cyclosporine.   
 Classical insulin resistance (insulin resistance that is secondary to faulty signaling 
downstream of the insulin receptor) is also increased in incidence in the SLE population.  Several 
studies have shown that SLE patients have increased fasting insulin compared to healthy controls 
(3, 38, 116, 167, 188, 209, 210).  This hyperinsulinemia is accompanied by increased levels of 
leptin and a paradoxical increase in adiponectin (176). The instigating factor for 
hyperinsulinemia in the context of SLE is not clear.  One candidate—adiposity—could be a 
contributing factor.  Although early studies showed higher body mass index (BMI) in cohorts of 
lupus patients (100, 101), subsequent studies failed to show significant differences in BMI 
between SLE patients and healthy controls (116, 167, 209, 210).  Another possible contributing 
factor could be the use of corticosteroids for the management of SLE.  Corticosteroids have been 
shown to cause changes in adipose distribution, hyperglycemia, beta cell impairment and 
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inhibition of insulin receptor signaling (94), so it is logical to conclude that they may cause the 
metabolic dysfunction seen in SLE patients.   However, studies of this subject have failed to 
yield a correlation between cumulative corticosteroid use and metabolic disease in SLE patient 
cohorts (37, 38, 116, 210).  Finally, the systemic inflammation present in the setting of SLE 
could be a contributing factor.  Studies in this area have been more fruitful and have yielded 
clues regarding the immunological changes that contribute to insulin resistance in SLE.  One 
study showed a strong positive correlation between the serum levels of the pro-inflammatory 
cytokine IL-18 and insulin levels in a lupus patient cohort (209), but another study failed to show 
a correlation between serum levels of IL-6 or TNF-α and insulin resistance.  Serum levels of IL-
18, a proinflammatory cytokine that is produced by macrophages, dendritic cells and Kupffer 
cells, has been shown to correlate with insulin resistance (208).  IL-18 is important in the 
activation of NK cells and T cells and serum IL-18 levels have been shown to be associated with 
many components of the metabolic syndrome in the general obese population (85) and in the 
SLE patient population (208).   
 Only one study of insulin resistance in a mouse model of lupus has been published (185). 
This study by Ryan et al. showed that lupus-prone NZB/W F1 mice had hyperinsulinemia, 
hyperleptinemia and higher glucose intolerance than control parental strain mice.  In the 
following chapter, we present data regarding glucose intolerance in the B6.SLE.1.2.3 mouse 
model of lupus which develop adipose tissue insulin resistance and glucose intolerance when fed 
low-fat diet.   
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CHAPTER II 
AUTOIMMUNE-MEDIATED INSULIN RESISTANCE IN A MOUSE MODEL OF 
SYSTEMIC LUPUS ERYTHEMATOSUS 
Introduction 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which 
pathogenic autoantibodies disrupt the functions of various organs and organ systems.  Causes of 
SLE mortality can be clustered into two main groups:  early mortality and late mortality (24, 61, 
214).  Early causes of mortality include glomerulonephritis, infection and neurological disease, 
whereas cardiovascular disease (CVD) is the main cause of late mortality (95, 181).  Clinical 
management of SLE has improved over the last decades, shifting the mortality burden from early 
causes to late causes.  As this burden shifts, it is important to understand the factors that 
contribute to the development of CVD in SLE patients.  SLE patients have been shown to have a 
higher prevalence of traditional CVD risk factors such as hyperlipidemia or hypertension and 
non-traditional, SLE-specific risk factors such as autoreactive immunoglobulin or corticosteroid 
therapy (24).  Additionally, metabolic syndrome is more prevalent in the SLE population (37, 56, 
116, 186) and may contribute to the increased CVD burden in these patients. 
The metabolic syndrome is characterized by the presence of obesity, IR, hypertension, 
and dyslipidemia (54, 96).  IR, a central component of type 2 diabetes mellitus (T2DM), is 
thought to be caused by chronic inflammatory processes involving complex interactions between 
cells of the metabolic and immune systems.  Several studies have yielded crucial information 
implicating visceral adipose tissue as a main focus of the chronic inflammation that can 
contribute to IR and T2DM.  Pro-inflammatory M1 macrophages accumulate in the adipose 
tissue of obese mice (223), and blocking macrophage accumulation attenuates IR in these 
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animals (222).  Subsequent studies have shown that the adaptive immune system mediates 
insulin resistance in obesity.  CD8
+
 T cells and B cells exacerbate insulin resistance in obese 
mice, whereas regulatory T cells protect against the development of insulin resistance (62, 151, 
224, 225). 
In the only other study of metabolic syndrome in an SLE model of which we are aware, 
Ryan et al. (185) showed that the (NZB/W)F1 lupus-prone strain has increased adiposity, 
increased adipose tissue macrophage infiltration and worsened glucose intolerance.  However, 
the contributions of the adaptive immune system to this metabolic phenotype was not examined 
and merits further study.   
We examined the pathogenesis of metabolic syndrome in the B6.SLE mouse model of 
SLE. The B6.SLE congenic strain is derived from the NZM2410 [(NZB/W)F1 X NZW] model 
of SLE, which develops severe lupus and nephritis in both genders (139).  Through linkage 
analyses, Morel et al., identified three major genomic intervals linked to lupus susceptibility in 
the strain (139). Using these three chromosomal intervals, termed Sle1, Sle2 and Sle3, the 
investigators made triple congenic mice on the C57Bl/6 background (140, 141). The B6.Sle1.2.3 
strain, also known as the B6.SLE strain, displays a fully penetrant lupus phenotype similar to that 
of humans.  In the current study, we present evidence that accelerated insulin resistance and 
disrupted glucose homeostasis in B6.SLE may be mediated by pathogenic B cells.  
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Materials and Methods 
Mice.  B6.Sle.1.2.3 mice, hereafter referred to as B6.SLE mice, were a generous gift of Edward 
Wakeland (UTSW, Dallas, TX) and have been previously described (139).  C57BL/6 mice (B6) 
were originally purchased from Jackson Labs (Bar Harbor, ME), and were bred in the animal 
facility at Vanderbilt University Medical Center.  All procedures involving animal subjects 
received prior approval from the Vanderbilt University Institutional Animal Care and Use 
Committee.  
Diet. B6 and B6.SLE mice were co-housed after weaning and fed low fat diet (LFD, 10% Kcal 
from fat, D12450B, Research Diets, New Brunswick, NJ) or HFD (HFD, 45% Kcal from fat, 
D12451, Research Diets, New Brunswick, NJ) ad libitum. 
Glucose Tolerance Tests.  Study mice were fasted for 5-6 hours on paper bedding before their 
tails were nicked under isoflurane anesthesia.  Mice were rested for 20 minutes and then injected 
i.p. with 1.25 g/kg lean body mass glucose.  Blood glucose was measured at baseline and at 15, 
30, 45, 60, 90 and 120 minutes after injection using a One Touch Ultra glucometer.   
Anti-dsDNA Antibody ELISA. Serum titers of anti-dsDNA antibodies were measured using the 
protocol described by  Shivakumar et al.(194).  Nunc MaxiSorp plates were blocked with mBSA 
in 1X PBS (0.1 mg/ml) at 37º C for 30 minutes.  The plate was then washed with PBS and coated 
with 50 μg/mL dsDNA in PBS at 37º C for 30 minutes.  The plate was washed twice with PBS 
and blocked overnight at 4º C with blocking buffer (3% BSA, 3 mM EDTA, and 0.1% gelatin in 
PBS).  The plates were washed twice with PBS.  The serum was diluted 1:1000 in serum diluent 
(2% BSA, 3mM EDTA, 0.05% Tween 20 in PBS) and added to plate and incubated 2 hours at 
RT on an orbital shaker.  The plate was washed twice in PBS-tween and twice in PBS.  IgG-HRP 
(Promega, Madison, WI) was diluted 1:5000 in secondary diluent (1% BSA and 0.05% Tween in 
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PBS), added to the plate and incubated overnight at 4º C on an orbital shaker.  The plate was 
washed twice with PBS-tween and twice with PBS and OptEIA TMB Substrate (BD 
Biosciences, San Diego, CA) was added to the plate and allowed to incubate.  The reaction was 
quenched with 1 M phosphoric acid and the plate was promptly read at 450nm. 
Islet Perifusion Assay. Pancreatic islets were isolated and assessed for secretory capacity as 
previously described (22, 219, 227).  Briefly, the pancreas was digested in a solution of 
collagenase P in Hank’s Balanced Saline Solution (HBSS) using a wrist-action shaker.  
Digestion was quenched with ice-cold 10% FCS/HBSS.  The digest was washed and islets were 
hand-picked under microscopic guidance.  Islet insulin secretion was analyzed in a dynamic cell 
perifusion system. The perifusion medium was Dulbecco's Modified Eagle Medium 
supplemented (Gibco) with 10 mM HEPES, 26 mM NaHCO3 and 0.1% BSA.  Fifty islet 
equivalents were placed in a chamber and washed under baseline media for 30 minutes prior to 
the experiment. Islets were then perifused for 9 minutes with 5.6 mM glucose (Sigma, D16), 
followed by 30 minutes with 16.7 mM glucose, 21 minutes with 5.6 mM glucose, 9 minutes with 
16.7 mM glucose + 50 μM isobutylmethylxanthine (IBMX, Sigma, I5879-1G), 21 minutes with 
5.6 mM glucose, 9 minutes with 20 mM KCl and 21 minutes with 5.6 mM glucose. The effluent 
fractions were collected at 3-minute intervals using an automatic fraction collector. The insulin 
concentration of each fraction was measured by radioimmunoassay (RI-13K, Millipore). 
Immunoglobulin ELISA.  Serum IgG was measured using conventional sandwich ELISA.  
Briefly, MaxiSorp ELISA plates (Nalge Nunc, Rochester, NY) were coated overnight with 0.5 
ug/mL IgG heavy and light chain (Southern Biotech, Birmingham, AL).  Plates were blocked 1h 
with 10% FBS in 1X PBS and serum samples or mouse reference serum (Bethyl Laboratories, 
Montgomery, TX) were incubated overnight at 4º Celsius.   Detection antibody [0.5 ug/ml biotin-
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conjugated anti-IgM , -IgG1, -IgG2c (Southern Biotech, Birmingham AL), or anti-IgG HRP-
conjugated antibody (1:2500) (Promega, Madison, WI)] was incubated 2 hours at RT.  
Streptavidin-HRP (1:2500)(Sigma, St. Louis, MO) was incubated in IgM, IgG1, or IgG2c wells 
for 1 hour at RT before plates were developed with OptEIA TMB Substrate (BD Biosciences, 
San Diego, CA). 
BAFF and Insulin ELISA. Serum BAFF was measured using a Quantikine Mouse 
BAFF/BlyS/TNFSF13B ELISA Kit (R&D Systems, Minneapolis, Minnesota, USA).  Serum 
insulin was measured using a Rat/Mouse Insulin ELISA kit (Millipore, St. Charles, Missouri, 
USA).   
Anti-insulin antibody ELISA.  Anti-insulin antibody titers were measured as described in Rojas 
et al. (180).  MaxiSorp ELISA Plates (Nalge Nunc, Rochester, NY, USA) were coated overnight 
at 37º C with human insulin at a concentration of 1 μg/mL in borate buffered saline (100mM 
Boric Acid, 25mM Sodium Borate, 150mM NaCl, pH 8.2-8.5).  Plates were washed 3 times with 
PBS-Tween, and serum was diluted 1:100 in PBS-Tween.  In order to measure the presence of 
polyreactive autoantibodies, sample serum was concurrently diluted 1:100 in PBS-Tween spiked 
with 50 μg/mL human insulin.  Both spiked and unspiked dilutions of sample serum were 
incubated 1 hour at room temperature on an orbital shaker.  Plates were washed 4 times in PBS-
Tween and an alkaline phosphatase conjugated anti-IgG antibody (Southern Biotech, 
Birmingham AL, USA) was added to the plate at a final dilution of 1:500 in VBS containing 
FBS (140 mM NaCl, 5 mM sodium barbital, 15 mM sodium azide, and 0.5% FBS).  The plate 
was washed 4 times with PBS-tween and PNPP substrate (Sigma-Aldrich, St. Louis, MO, USA) 
was added and the plate was read at 405 nM when sufficient development had occurred. 
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Tissue Preparation. Perigonadal fat pads were minced and digested for 30 minutes at 37° C with 
agitation in 1 mg/ml collagenase in HBSS (Sigma, St. Louis, Missouri).  Digested tissue was 
passed through a 40 micron filter and leukocytes were isolated from the interface of a 40%/60% 
Percoll gradient (GE Healthcare, Piscataway, NJ).  Livers were collected and crushed through a 
40 micron filter and leukocytes were isolated from the interface of a 40%/60% Percoll gradient. 
Flow Cytometry.  Single-cell suspensions of liver mononuclear cells and stromal vascular cells 
were isolated as described above.  In order to minimize non-specific binding of flow antibodies, 
cells were blocked for 15 minutes at RT with a 1:200 dilution of Fc receptor block (BD 
Biosciences, San Diego, CA) in a FACS buffer consisting of 1X HBSS, 1% BSA, 4.1663 mM 
sodium bicarbonate and 3.0765 mM sodium azide.  The following fluorescently-labeled 
antibodies were diluted 1:200 in FACS buffer and incubated with the cells for 45 minutes at 4º 
C:  CD19-PECy7, B220-A450, TCRβ-PECy7, IgG-FITC, IgM-PE, IgD-APC, CD80-APC, and 
F4/80-PECy7, CD8-FITC, CD4-APCCy7, and BAFFR-PE  (BD Biosciences, San Diego, CA).  
The labeled cells were washed 3 times with FACS buffer and fixed overnight at 4º C in a 
solution of 2% paraformaldehyde in PBS.  Labeled cells were analyzed on a MACSquant seven-
color flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany) and data was analyzed 
with FCS Express 4 (De Novo Software, Los Angeles, CA). 
Immunoblotting.  Mice were fasted on paper bedding for four hours and then injected with 
1U/Kg body weight insulin.  Fifteen minutes later, mice were sacrificed and liver, soleus, 
gastrocnemius and perigonadal fat pads were removed and freeze clamped in liquid nitrogen. Fat 
was homogenized in a solution of 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 10% 
glycerol, 1% Triton X-100, 1 mM DTT, 1 mM PMSF, 5 mg/mL protease inhibitor, 50 mM NaF, 
and 5 mM sodium pyrophosphate and centrifuged for 10 minutes at 13,000 RPM at 4º C.  The 
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lysate was run on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane.  The 
membrane was probed with Akt primary rabbit antibody (1:1000)(Cell Signaling, Danvers, MA) 
or pAKT primary rabbit antibody (1:1000)(Cell Signaling, Danvers, MA) and incubated 
overnight at 4° C.  The membrane was then incubated for 1 hour at RT with anti-beta-actin 
antibody (1:1000)(Sigma Aldrich, St. Louis, MO) followed by incubation with goat anti-rabbit 
800LT conjugated secondary antibody (1:5000)( Li-Cor, Lincoln, NE) and goat anti-mouse 
680LT conjugated secondary antibody (1:20,000) and for 1h at RT.  Gels were scanned using a 
Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE) and bands were quantified using 
Odyssey Version 3.0 software (Li-Cor, Lincoln, NE).   
Serum cholesterol, serum triglycerides, and liver triglycerides.  Mice were fasted on paper 
bedding for 4 hours and blood was collected via the retro-orbital sinus under isoflurane 
anesthesia.  Blood was allowed to clot for 20 minutes and was subsequently spun at 13,000 RPM 
for 20 minutes at 4º C. Serum was collected, protease inhibitor cocktail was added and the 
samples were stored at -80º C.  Serum was thawed and diluted 1:100 with dH20 and triglyceride 
and cholesterol were measured using a Cholesterol and Triglyceride Enzymatic Assay according 
to the manufacturer’s protocol (Cliniqa Corporation, San Marcos, CA). 
Lipids were extracted from the liver using the method of Folch-Lees (64).  Individual 
lipid classes were separated by thin layer chromatography and visualized by rhodamine 6G.   
Triglycerides were scraped from the plates and methylated using BF3 /methanol as described by 
Morrison and Smith (142).  The methylated fatty acids were extracted and analyzed by gas 
chromatography.   Gas chromatographic analyses were carried out on an Agilent 7890A gas 
chromatograph equipped with flame ionization detectors, a capillary column (Supelco, 
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Bellefonte, PA).  Helium was used as a carrier gas and fatty acids were identified by comparing 
the retention times to those of known standards.   
Adipocyte size measurement. Peri-gonadal fat pads were collected and fixed in a phosphate-
buffered solution containing 10% formalin.  Fat was embedded in paraffin, sectioned and stained 
with hematoxylin and eosin. Adipocyte size was quantified by capturing 4 independent fields per 
blinded slide and measuring adipocyte area using ImageJ software (National Institutes of Health, 
Bethesda, MD). Average adipocyte size was calculated and expressed as μm2/adipocyte. 
Multiplex adipokine assay and C-Peptide ELISA   Study mice were fasted for 4 hours on paper 
bedding and blood was collected from the retro-orbital sinus under isoflurane anesthesia.  Blood 
was allowed to clot for 20 minutes and was subsequently spun at 13,000 RPM for 20 minutes at 
4º C. Serum was collected, protease inhibitor cocktail was added and the samples were stored at -
80º C.  A Milliplex mouse adipokine assay (Millipore, Billerica, MA) was used to measure 
insulin, leptin, resistin, IL-6 and TNF-alpha according to manufacturer instructions.  Serum C-
Peptide was measured using Millipore C-Peptide 2 ELISA kit according to manufacturer’s 
instructions. 
Statistics. Statistical significance for GTT data was calculated with a two-way ANOVA for 
repeated measures.  All other significance was calculated with a Student’s t test comparing mice 
within diet groups.  All calculations were completed with GraphPad Prism software (GraphPad 
Software, Inc., La Jolla, CA).  Unless otherwise noted, all data was expressed as mean +/- SEM. 
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Results 
B6.SLE Mice Are Prone to Autoimmunity.  Increased production of pathogenic anti-dsDNA 
antibodies and splenomegaly are hallmarks of autoimmune disease in B6.SLE mice.  Five-week-
old male B6 and B6.SLE mice were placed on LFD or HFD.  After twenty weeks of diet feeding, 
 
both anti-dsDNA antibody titers and spleen weight (Figure 2) were significantly increased in 
B6.SLE mice relative to their respective controls.  Interestingly, splenomegaly was more 
pronounced in HFD-fed B6. SLE mice than LFD-fed B6.SLE mice but there was no difference 
in anti-dsDNA antibody titers between B6.SLE mice of each diet group.  Although the markers 
of autoimmunity were significantly increased, there was no increased mortality in B6.SLE mice 
after 20 weeks of feeding as compare B6 controls (data not shown). 
Weight and Body Composition of B6.SLE Mice Varies from B6 Controls. Total body mass was 
measured weekly after LFD and HFD was initiated (Figure 3a, left panel). The baseline weights 
Figure 2.  B6.SLE mice are prone to autoimmunity.  (a) Five-week-old B6 and B6.SLE male mice were 
fed LFD (10% Kcal from fat) or HFD (45% Kcal from fat) for 20 weeks and blood was collected via the 
retro-orbital sinus.  Anti-dsDNA antibody titers were measured via ELISA and normalized to stock control 
serum. n=6-15/group (b) Five-week-old B6 and B6.SLE male mice were fed LFD or HFD 20-25 weeks.  
Spleen weight was measured after sacrifice.  (n=6-15/group). *p<0.005 via Student’s t test. 
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of B6.SLE mice in both diet groups were higher than their respective controls and remained 
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Figure 3.  Measurement of body mass and composition of B6 and B6.SLE mice.  (a)  Five-week-old B6 
and B6.SLE male mice were fed LFD or HFD and total body weight was measured weekly. n=3-5/group.  
Data are expressed as total body mass (left) and change in body mass from baseline (right). (b) Five-week-old 
B6 and B6.SLE male mice were LFD (10% Kcal from fat) or HFD (45% Kcal from fat) and body 
composition was measured with a Bruker MiniSpec NMR analyzer after 20 weeks of feeding. *p<0.05 via 
Student’s t test. 
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elevated for the duration of the experiment.  Weight gain, as expressed as change in body weight 
from baseline (Figure 3a, right panel), was not significantly different between B6 and B6.SLE 
mice in each diet group.  Lean body mass and adipose tissue mass were assessed in all groups 
after 20 weeks of feeding (Figure 3b).  Adiposity was not significantly different between LFD-
fed B6.SLE and B6 mice at this time point.  However, lean body mass was significantly higher in 
LFD- and HFD-fed B6.SLE groups as compared to B6 controls and partially accounted for the 
increased body weight observed in LFD-fed B6.SLE mice in Figure 3a.   
Glucose Homeostasis and Insulin Receptor Signaling is Altered in B6.SLE Mice. Glucose 
tolerance tests were conducted in male B6.SLE and B6 mice after 20 weeks of LFD or HFD 
feeding (Figure 4a and b).  Glucose intolerance was significantly higher in B6.SLE mice than 
their respective B6 controls in the LFD-fed groups when data was expressed as absolute blood 
glucose level (Figure 4a) or as the area under the curve (Figure 4b).  Interestingly, the glucose 
curve of LFD-fed B6.SLE mice approached the curve of HFD-fed B6 mice.   
In order to determine whether insulin signaling is disrupted in metabolically active tissues 
in B6.SLE mice, Western blotting was used to measure the phosphorylated-Akt-to-Akt ratio in 
the perigonadal fat pads, liver, soleus muscle and gastrocnemius muscle.  Akt is a critical 
component of the insulin signaling pathway and becomes phosphorylated after the insulin 
receptor is ligated, ultimately causing translocation of the GLUT4 glucose transporter to the cell 
surface.  The pAkt-to-total-Akt ratio was significantly reduced in the adipose tissue of LFD-fed 
B6.SLE mice relative to B6 controls (Figure 4c), indicating that insulin signaling is impaired in 
the adipose tissue of LFD-fed SLE mice.  No significant difference in Akt phosphorylation was 
seen in LFD-fed strains in the liver, gastrocnemius or soleus muscle although trends toward 
lower ratios of phosphorylation 
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 Figure  4.  Glucose homeostasis and insulin receptor signaling is impaired in B6.SLE mice.  Five-week-
old B6 and B6.SLE male mice were fed low fat diet or high fat diet for 20 weeks.  After 5-6 hours of fasting, 
mice were injected with 1.25 g glucose per kg lean body weight and blood glucose was measured using a 
One Touch Ultra glucometer.  n=16-25 mice/group in four independent experiments. Data are expressed as 
blood glucose over time (a) or area under the glucose excursion curve (b). **p<0.0001 between LFD-fed 
B6.SLE and B6 mice via two-way ANOVA. ***p<0.0001 via Student’s t test.  (c)  After 20 weeks of HFD 
or LFD feeding, mice were fasted for four hours and then injected with 1U/Kg lean body weight insulin.  
Fifteen minutes later, mice were sacrificed and liver, gastrocnemius, soleus and perigonadal fat was removed 
and freeze clamped in liquid nitrogen. Tissue lysate was analyzed by Western blot with Akt and pAkt 
antibodies.  Data is expressed as integrated intensity of Akt or the ratios of the integrated intensity of pAkt 
and Akt. n=3-5 mice/group. Values are expressed as mean +/- SEM. *p<0.04 via Student t test. 
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in B6.SLE mice were observed.  No significant differences in pAkt ratios were seen between 
strains in any of the tissues in HFD-fed groups.  
B6.SLE Islets Have Increased Insulin Secretion.  In order to determine whether the observed 
glucose intolerance is due to impaired beta cell function, pancreatic islets were isolated from 
LFD-fed B6 and B6.SLE mice and responses to several beta cell secretagogues were measured in 
an islet perifusion system.  Figure 5a shows that insulin secretion was significantly increased in 
the islets of LFD-fed B6.SLE mice in response to 16.7 mM glucose, 16.7 mM glucose + 50 M 
IBMX, and 20 mM KCl, ruling out beta cell defects in glucose sensing, metabolism or granule 
exocytosis in LFD-fed B6.SLE mice.   
Circulating Adipokines and Cytokines are Not Different in LFD-fed B6.SLE Mice.  To 
determine if circulating adipokines and cytokines contribute to glucose intolerance in B6.SLE 
mice, fasting levels of leptin, resistin, IL-6, TNFα and insulin were measured using a cytokine 
 
Figure 5. B6.SLE pancreatic islets have increased insulin secretion. Male mice were fed LFD for 20 
weeks before sacrifice. Function of size-matched pancreatic islets was assessed in a cell perifusion 
apparatus in response to several beta cell secretagogues. Data is expressed as ng insulin per 100 islet 
equivalents (IEQs) per minute (a) or area under the curve (AUC) for each secretagogue (b). n=3-4/group.  
Statistical analysis was performed by a Student’s t test. 
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bead array, and fasting glucose was measured using a handheld glucometer.  As seen in Figure 6, 
no differences in fasting insulin or fasting glucose were observed between strains in the LFD-fed 
groups and there was a non-significant trend toward higher glucose and insulin in HFD-fed B6 
mice relative to HFD fed B6.SLE mice   Insulin clearance was estimated by measuring the ratio 
of fasting serum insulin to fasting serum C-peptide 2 in LFD-fed mice.  C-peptide 2 is cleaved 
from the pro-insulin molecule during the formation of insulin (184).  C-peptide 2 is cleared in the 
kidney (242) and insulin is primarily cleared in the liver (53), and the ratio of these two 
molecules can be used to estimate hepatic clearance of insulin. There was no difference in the C-
peptide to insulin ratio between B6.SLE and B6 mice, which suggests that SLE disease does not 
affect the rate of insulin clearance in B6.SLE mice. 
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Figure 6. Fasting adipokines, cytokines, insulin and glucose in the serum of B6.SLE mice.  Male mice 
were fed LFD or HFD for 20 weeks before sacrifice.  Mice were fasted 4 hours and blood was collected via the 
retro-orbital sinus.  Glucose levels were measured with a handheld glucometer and C-Peptide was measured 
with sandwich ELISA. Insulin, resistin, leptin, and TNF-α were measured with a multiplex adipokine assay.  
n=8-11/group. *p<0.02 by Student’s t test. **p<0.009 by Student’s t test. 
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Levels of serum resistin and leptin in LFD-fed groups were indistinguishable, and levels 
of resistin and leptin were significantly lower in HFD-fed B6.SLE mice relative to HFD-fed B6 
controls.  There was a trend toward higher TNF-α in HFD-fed B6.SLE mice relative to controls, 
but no increase in serum TNF-alpha was seen in LFD-fed B6.SLE mice.  IL-6 levels were below 
the level of assay detection in all groups.  Collectively, these results suggest that the glucose 
intolerance and adipose tissue insulin resistance observed in LFD-fed mice is not instigated by 
adipokines or cytokines normally associated with insulin resistance and may result from SLE-
specific factors.   
 
Adipocyte Size is Increased in B6.SLE Mice. Increased adipocyte size has been correlated with 
glucose intolerance and adipose tissue insulin resistance.  In order to determine whether B6.SLE 
mice have increased adipocyte size, we measured adipocyte size in paraffin-embedded adipose 
tissue.  As seen in Figure 7, average adipocyte size was significantly greater in LFD-fed B6.SLE 
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Figure 7.  Measurement of adipocyte area.  Male mice were fed LFD or HFD for 20 weeks before sacrifice.  
Perigonadal fat pads were fixed, sectioned and stained with H&E and adipocyte area was quantified.   n=3-
4/group. *p<0.0005 by Student’s t test. 
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mice relative to B6 controls.  There was no difference in average adipocyte size between HFD-
fed B6.SLE mice and their controls.   
 
Serum Cholesterol, Serum Triglyceride, and Liver Triglyceride are Significantly Reduced in 
B6.SLE Mice.  We measured serum cholesterol and triglycerides in study mice in order to 
determine whether lipid homeostasis is perturbed in B6.SLE mice.  As seen in Figure 8a, serum 
cholesterol and triglyceride levels are significantly decreased in HFD- and LFD-fed B6.SLE 
mice relative to their respective controls.  Liver triglyceride content (Figure 8b) is significantly 
decreased in HFD-fed B6.SLE mice relative to B6 controls and there is a non-significant trend 
towards reduced triglyceride content in the livers of LFD-fed B6.SLE mice.   
Leukocyte Content in the Stromal Vascular Fraction Varies in SLE Mice. Cells of the adaptive 
and innate immune systems have been associated with adipose tissue dysfunction in mouse 
models of obesity.  In order to examine the immune compartment in study mice, we used flow 
cytometry to assess the cell content of the SVF in LFD- and HFD-fed mice after 20 weeks of 
feeding.  No significant difference was seen in the percentage of total CD19
+ 
B cells in the SVF 
(Figure 9a) in either diet group.  There were no differences in antigen presenting cell content of 
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Figure 8.  Measurement of serum triglyceride and cholesterol.  (a) Male mice were fed LFD or HFD for 20-
25 weeks before sacrifice.  Blood was collected via the retro-orbital sinus and serum cholesterol and 
triglyceride was measured using a commercially available enzymatic assay. n=8-11 mice/group.  *p<0.005 by 
Student’s t test.  (b)  Male mice were fed HFD or LFD for 20-25 weeks before sacrifice.  Livers were harvested 
and triglyceride content was measured with gas chromatography.  n=4-10/group. *p<0.05 by Student’s t test. 
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the SVF between strains within each diet group as measured by F480, a marker of both 
macrophages and dendritic cells (Figure 9b).  These findings indicate that F480+ cell 
infiltration—known to be associated with insulin resistance in obese mice—is not correlated with 
 
glucose intolerance and adipose insulin resistance in B6.SLE mice.  TCRβ+ T cell content in the 
SVF of HFD- and LFD-fed B6.SLE was significantly higher than their respective B6 controls 
(Figure 9c).  Additionally,  the proportion of CD8+ T cells—but not CD4+ T cells—in LFD-fed 
B6.SLE mice was significantly increased relative to controls and exceeded the percentages of 
CD8+ T cells in HFD-fed B6 mice  (Figure 9d-e).  This increase in CD8+ T cell parallels the 
results of Nishimura et al. in which HFD-feeding caused an increase in CD8+ T cells which 
correlated with insulin resistance in their study (151). 
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Figure 9.  Flow cytometry analyses of the SVF of B6 and B6.SLE mice fed LFD or HFD.  Mice 
were fed LFD or HFD for 20-25 weeks before sacrifice.  (a-e) SVF cells were isolated by digesting 
the perigonadal fat pads in collagenase followed by percoll gradient centrifugation. Cells were 
stained and analyzed using conventional flow cytometry techniques. n=5-8 mice/group. *p<0.05 by 
Student’s t test. 
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Figure 10.  Stromal vascular fraction B cells in B6.SLE Mice are skewed towards IgG production and 
show higher expression of an activation marker.  (a) Mice were fed LFD or HFD for 20-25 weeks before 
sacrifice.  SVF cells and hepatic mononuclear cells were isolated by digesting the perigonadal fat pads in 
collagenase followed by percoll gradient centrifugation.  Cells were stained and analyzed using conventional 
flow cytometry techniques. n=6-8 mice/group. *p<0.05 by Student’s t test.  (b) Male mice were fed LFD or 
HFD for 20-26 weeks and serum levels of IgG1, IgG2c, IgM and total Ig were measured using conventional 
sandwich ELISA.  ELISA absorbances were normalized to LFD-fed B6 controls. n=6-16/group. *p<0.0005 by 
Student’s t test. (c) Perigonadal fat pads and liver were harvested from male B6 and B6.SLE mice. After 
probing for Akt, phospho-Akt and beta-Actin (Fig. 3c) the nitrocellulose blots were stripped and probed for 
IgG. Data is expressed as the ratio of the integrated intensity of the IgG heavy chain band to the integrated 
intensity of the beta actin band. N=6-8/group in fat, 3-6/group in liver. *p<0.05 by Student’s t test. (d) Mice 
were fed LFD or HFD for 20-25 weeks before sacrifice.  SVF cells were isolated by digesting the perigonadal 
fat pads in collagenase followed by percoll gradient centrifugation.  Cells were stained for CD80 and analyzed 
using conventional flow cytometry techniques. n=5-8 mice/group. *p<0.05 by Student’s t test.  
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Stromal Vascular Fraction B Cells in B6.SLE Mice Are Skewed Towards IgG production. 
Although no quantitative differences were observed in the CD19
+
 B cell population in study 
mice, we hypothesized that B6.SLE mice were predisposed to develop qualitative differences in 
the SVF-resident B cell population.  Previous studies by Winer et al. 
19
 have shown that B cells 
contribute to adipose tissue insulin resistance through production of pathogenic IgG antibodies.  
We investigated whether SVF resident B cells had undergone class-switch recombination by 
using flow cytometry to quantify IgD, IgM and IgG expression on CD19
+
 B cells (Figure 10a). 
The percentage of class-switched IgG
+
 B cells in B6.SLE mice was significantly higher than B6 
controls in each diet group.  No differences in IgG
+
 B cell ratios were observed in the liver, 
indicating that these changes are specific to the gonadal fat pad.  To determine whether systemic 
Ig levels were altered in B6.SLE mice, circulating total IgG, IgG1, IgG2c and IgM were 
measured in serum collected from male mice fed for 20-26 weeks (Figure 10b). LFD- and HFD-
fed B6.SLE mice had significantly higher circulating total IgG, IgG1, IgG2c and IgM than their 
respective B6 controls.   Perigonadal fat pad lysates were probed for IgG heavy chain in order to 
determine whether SLE mice had higher adipose tissue IgG deposition than B6 controls.  As seen 
in Figure 10c, there was significantly more IgG heavy chain in the perigonadal fat pads of LFD-
fed B6.SLE mice as compared to LFD-fed B6 controls.   Furthermore, there was significantly 
more IgG deposition in the livers of LFD- and HFD-fed B6.SLE mice relative to their B6 
controls.   Finally, the expression of the activation marker CD80 was significantly increased in 
SVF B cells of LFD-fed B6.SLE mice (Figure 10d).  Type B insulin resistance is caused by 
autoantibodies against insulin and the insulin receptor and has been associated with SLE (93).  A 
modified ELISA was used to determine whether the glucose intolerant phenotype in B6.SLE 
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mice is due to anti-insulin antibodies.  As seen in Figure 11, the titers of anti-insulin antibodies 
were not significantly different than that of control mice, indicating that the antibody detected in 
the adipose tissue may be causing effects through reacting with antigens other than insulin.     
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Figure 11.  Insulin-specific IgG Antibodies Are Not In the Circulation of B6.SLE Mice.  Male mice 
were fed HFD or LFD for 20 weeks and blood was collected via the retro-orbital sinus.  A modified ELISA 
was used to detect insulin-specific antibodies in the serum of these mice.  Data are expressed as the 
difference in absorbance between the uninhibited samples and the corresponding insulin-inhibited samples.  
n=3-10 mice/group. 
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Figure 12.  Measurement of BAFF and BAFFR.  (a) Male mice were fed HFD or LFD for 16-25 weeks 
before sacrifice.  Blood was collected via the retro-orbital sinus and serum BAFF was measured using 
conventional sandwich ELISA. n=6-8 mice/group.  *p<0.05, **p<0.0007 by Student’s t test.  (b) Female 
mice were fed HFD or LFD for 30 weeks before sacrifice.  SVF cells were stained and analyzed using 
conventional flow cytometry techniques. n=5-8 mice/group. *p<0.05 by Student’s t test. 
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Overall, the data show that SVF B cells are skewed towards a pro-inflammatory IgG response, 
that circulating IgG1 levels are elevated in the serum of B6.SLE mice and that there is increased 
IgG deposition in the fat pads of B6.SLE mice.   
Circulating BAFF is Increased in the Serum of B6.SLE Mice. B cell Activating Factor (BAFF) 
is a growth factor that promotes proliferation, maturation and antibody production of B cells.  
Elevated levels of circulating BAFF have been observed in the context of SLE and may be 
associated with increased disease severity and production of pathogenic autoantibodies (26).  
Furthermore, BAFF has been shown to impair insulin signaling in adipocytes in vivo and in vitro 
(80).  To determine whether circulating BAFF levels are elevated in the B6.SLE strain, we 
collected serum from male mice fed diet for 16-25 weeks.  BAFF levels were significantly 
elevated in LFD- and HFD-fed mice relative to their B6 controls (Figure 12).  There was a trend 
towards higher BAFF levels in HFD-fed B6.SLE relative to LFD-fed B6.SLE mice, indicating 
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Figure 13.  Female B6.SLE mice are prone to autoimmunity. (a) Five-week-old B6 and B6.SLE female 
mice were fed LFD or HFD 30 weeks.  Spleen weight was measured after sacrifice.  n=7-11/group. (b) 
Five-week-old B6 and B6.SLE female mice were fed LFD (10% Kcal from fat) or HFD (45% Kcal from 
fat) for 30  weeks and blood was collected via the retro-orbital sinus.  Anti-dsDNA antibody titers were 
measured via ELISA and normalized to stock control serum. n=5-6/group *p<0.05 via Student’s t test. 
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that HFD feeding may be associated with higher BAFF levels in these mice.  BAFF receptor  
(BAFFR) is expressed on mature peripheral B cells and its ligation promotes cell survival 
through activation of Bcl-2 survival pathway (26).  We used flow cytometry to determine 
whether SVF B cells from male B6.SLE mice had different levels of BAFFR expression than 
controls (Figure 12b-c).  B6.SLE mice had trends towards higher BAFFR expression than B6  
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Figure 14.  Measurement of body mass and composition of female B6 and B6.SLE mice.  (a)  Five-
week-old B6 and B6.SLE female mice were fed LFD or HFD and total body weight was measured weekly. 
n=3-5/group.  Data is expressed as total body mass (left) and change in body mass from baseline (right). (b) 
Five-week-old B6 and B6.SLE female mice were LFD (10% Kcal from fat) or HFD (45% Kcal from fat) 
and body composition was measured with a Bruker MiniSpec NMR analyzer after 30 weeks of feeding. 
n=5-10/group. *p<0.05 via Student’s t test. 
 
 
 49 
 
 
mice and LFD-fed B6.SLE mice and there were trends towards higher BAFFR expression in  
HFD-fed groups relative to their respective LFD-fed groups.  Taken together, these data suggest 
an environment in which B cells in HFD-fed B6.SLE mice are predisposed to greater activation 
and survival due to higher levels of circulating BAFF and increased expression of BAFF receptor 
on SVF B cells.  
Similarities and Differences in Metabolic Disease in Male and Female B6.SLE Mice 
Female B6.SLE mice develop similar autoimmune disease to male mice and generate anti-
dsDNA antibody titers and severe splenomegaly (Figure 13a-b). Metabolic disease was also 
assessed in female B6.SLE mice fed LFD or HFD for 30 weeks.  Unlike male B6.SLE mice, 
female mice gain significantly more weight than their respective B6 controls when data is 
expressed as absolute body weight and change in weight from baseline (Figure 14a).  LFD-fed 
B6.SLE mice had significantly higher lean body mass and a trend towards lower fat mass than 
controls.  Similarly, HFD-fed B6.SLE mice had trends towards higher lean body mass and lower 
adipose tissue mass than controls (Figure 14b). Unlike male B6.SLE mice, significant worsened 
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Figure 15.  Glucose homeostasis is impaired in female B6.SLE mice.  Five-week-old B6 and B6.SLE female 
mice were fed low fat diet or high fat diet for 30 weeks.  After 5-6 hours of fasting, mice were injected with 1.25 
g glucose per kg lean body weight and blood glucose was measured using a One Touch Ultra glucometer.  n=16-
25 mice/group in four independent experiments. Data are expressed as blood glucose over time (a) or area under 
the glucose excursion curve (b). *p<0.05 between LFD-fed B6.SLE and B6 mice via two-way ANOVA (a) and 
(b) or *p<0.05 by Student’s t test (c).   
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Figure 16. SVF B cells in female B6.SLE Mice are skewed towards IgG production.  (a) Mice were fed LFD 
or HFD for 30 weeks before sacrifice.  SVF cells and hepatic mononuclear cells were isolated by digesting the 
perigonadal fat pads in collagenase followed by percoll gradient centrifugation.  Cells were stained and analyzed 
using conventional flow cytometry techniques. n=5-10 mice/group. *p<0.05 by Student’s t test.  (b) Female 
mice were fed LFD or HFD for 30 weeks and serum levels of IgG1, IgG2c, IgM and total Ig were measured 
using conventional sandwich ELISA.  ELISA absorbances were normalized to LFD-fed B6 controls. N=7-
11/group. *p<0.05 by Student’s t test.  
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Figure 17.  Serum levels of BAFF in female B6 and B6.SLE mice. Female mice were fed HFD or LFD for 30 
weeks before sacrifice. (a)  Blood was collected via the retro-orbital sinus and serum BAFF was measured using 
conventional sandwich ELISA. n=5-8 mice/group *p<0.05, **p<0.007 by Student’s t test. (b) and (c) Female 
mice were fed HFD or LFD for 30 weeks before sacrifice.  SVF cells were stained and analyzed using 
conventional flow cytometry techniques. n=3-5 mice/group. *p<0.05 by Student’s t test. 
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glucose intolerance was seen in the HFD-fed B6.SLE group whereas there was only a slight 
trend toward higher glucose intolerance in the LFD-fed B6.SLE group (Figure 15).  Like male 
mice, female B6.SLE mice had increased proportions of IgG class-switched B cells in the 
stromal vascular fraction (Figure 16a) and increased circulating IgG, IgG1, IgG2c and IgM 
relative to controls in both diet groups (Figure 16b).  Furthermore, BAFF levels were 
significantly higher in B6.SLE relative to controls in both diet groups (Figure 17a) and there was 
significantly higher BAFF receptor expression on SVF-resident B cells in HFD-fed B6.SLE mice  
(Figure 17b-c). 
Discussion 
In this report, we show for the first time that B6.SLE mice develop more severe glucose 
intolerance and adipose tissue insulin resistance than B6 controls and that B6.SLE B cells have a 
diabetogenic immunophenotype characterized by increased circulating IgG, increased IgG 
expression on B cells and increased deposition of IgG heavy chain in white adipose tissue (80, 
224).  These changes were observed in LFD-fed B6.SLE mice, indicating that SLE disrupts 
glucose metabolism in the context of a low fat diet.  Adiposity did not vary significantly between 
B6.SLE mice and their controls, indicating that lupus-related immune dysregulation—and not 
adipose tissue accumulation—causes disruption of glucose homeostasis in mice.  Assessment of 
pancreatic islet function showed increased glucose-stimulated insulin secretion in B6.SLE islets. 
However, there was not a concomitant increase in fasting serum insulin in B6.SLE mice, which 
could be explained by either increased insulin clearance or lower islet cell mass.  Estimation of 
insulin clearance with the C-peptide-to-insulin ratio (Figure 6a, Right Panel) showed no 
difference between mouse strains. Collectively, these data suggest that B6.SLE mice may be 
compensating for lower islet cell mass by increasing islet secretory capacity.  Islet cell mass was 
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not measured, so we cannot confirm there is a defect in islet cell mass in B6.SLE mice in the 
present study. 
These findings contrast with the earlier mouse studies of Ryan et al. (185) in the NZW/F1 
model of lupus, in which NZW/F1 mice were shown to have hyperinsulinemia, hyperleptinemia 
and higher glucose intolerance than control parental strain mice.  Our study differs from that of 
Ryan et al. in several key areas.  Firstly, the NZW/F1 mice in Ryan et al. study reported 
significantly larger white adipose depots than controls.  In some cohorts, NZW/F1 mice had 
twice as much visceral adipose tissue than controls, making it difficult to determine whether the 
metabolic differences observed were due to changes in body composition or the immune 
dysregulation observed in the setting of SLE.  Our study shows that B6.SLE mice have 
decreased glucose tolerance and adipose tissue insulin resistance despite having similar adipose 
tissue mass and increased lean mass relative to controls.  Secondly, given the newly-
characterized importance of the adaptive immune system in metabolic syndrome and the critical 
role of the adaptive immune system in the pathogenesis of SLE, our studies focused on the 
immunophenotype of the SVF lymphocyte compartment.  We observed significantly increased 
percentages of T cells in the SVF of LFD-fed B6.SLE mice relative to controls.  Although no 
differences in total B cell proportions were detected in B6.SLE mice on either diet, there were 
several qualitative differences in the B cell compartment.  Specifically, the proportion of IgG-
positive B cells was significantly increased in both diet groups and the activation marker CD80 
was increased on B cells in LFD-fed B6.SLE mice.  Circulating IgG was increased in the 
periphery of B6.SLE mice on both diets and there was a significant increase in IgG deposition in 
the adipose tissue of B6.SLE mice.  These results are consistent with the diabetogenic B cell 
immunophenotype described by Winer et al. (224), in which IgG antibody secreted by B cells in 
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the context of HFD contributed to insulin resistance.  Future studies will focus on whether 
passive immunization with IgG from LFD-fed B6.SLE mice is sufficient to induce glucose 
intolerance and adipose tissue insulin resistance in recipient mice. 
Adipocyte hypertrophy in visceral adipose tissue has been associated with insulin 
resistance and hyperlipidemia.  Although we observed increased adipocyte size in LFD-fed 
B6.SLE mice relative to controls, there were decreases in serum triglyceride and cholesterol in 
B6.SLE mice.  We have previously observed reduced triglyceride and cholesterol levels in 
studies of B6.SLE mice (21, 199) and other groups have shown similar changes in serum lipids 
in patients with rheumatoid arthritis and other autoimmune diseases (88, 114, 183, 189, 204).  
The mechanism that causes this phenomenon is not known, but may result from disruption of 
lipid homeostasis by the chronic inflammation present in autoimmune disease (204).   
Fasting levels of glucose, insulin, leptin, resistin, TNFα, and IL-6 were not significantly 
different between LFD-fed B6.SLE mice and their controls.  This may indicate that the metabolic 
phenotype only becomes unmasked after challenge with glucose or insulin, or that the phenotype 
is only apparent in the fed state.  Levels of glucose, insulin, leptin and resistin in the fed state 
have not been measured in the current study. Furthermore, we observed worsened glucose 
tolerance and adipose tissue insulin resistance in LFD-fed B6.SLE mice (Figure 4c) which was 
not accompanied by significant insulin resistance in liver or skeletal muscle.  Adipose-tissue-
specific impairment of insulin signaling has been shown to ameliorate glucose intolerance  in fat-
specific insulin receptor knockout (FIRKO) mice (16).  Within this paradigm, we would not 
anticipate that the LFD-fed B6.SLE mice would have significantly worsened glucose tolerance.  
However, it is possible that non-classical, SLE-mediated effects on adipose tissue may be 
causing the observed metabolic impairment in B6.SLE mice. One molecule associated with both 
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SLE and impairment of adipocyte function is B cell activating factor (BAFF).  We observed 
increased levels of circulating BAFF in B6.SLE mice, and SVF-resident B cells in these mice 
had elevated expression of the BAFF receptor.  B cell Activating Factor (BAFF) is a growth 
factor that promotes proliferation, maturation and antibody production of B cells.  Elevated 
levels of circulating BAFF have been observed in the context of SLE and is associated with 
increased disease severity and production of pathogenic autoantibodies (26). In addition, 
adipocytes have been shown to express the BAFF receptor and  BAFF has been shown to 
specifically disrupt glucose homeostasis both in vitro and in vivo (80).  Future studies will focus 
on the role of BAFF and IgG in the pathogenesis of metabolic disease in the context of B6.SLE 
mice.   
Adiposity of B6.SLE mice did not differ significantly from that of B6 mice.  Although 
early studies in humans showed higher body mass index (BMI) in cohorts of lupus patients (100, 
101), subsequent studies failed to show significant differences in BMI between SLE patients and 
healthy controls (116, 167, 209, 210).   In one of these studies, Magadmi et. al reported that SLE 
patients had significantly worsened insulin resistance than healthy control patients , but body 
composition did not differ significantly between SLE and control groups and SLE patients were 
only moderately overweight (BMI=26.6) (116).  The observations of Magadmi et al. have been 
corroborated by several other groups (1, 27, 36).  Therefore, we propose that the LFD-fed 
B6.SLE mice are a very suitable model of SLE-associated metabolic disease.  Unexpectedly, 
reductions in glucose tolerance and insulin signaling were not observed in HFD-fed B6.SLE 
mice relative to B6 controls.  It is possible that HFD feeding “saturates” the phenotype of 
B6.SLE mice, making it difficult to detect differences in glucose tolerance and insulin signaling 
between strains.    Subsequent studies will focus on LFD-fed B6.SLE mice. 
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In conclusion, we have shown that B6.SLE mice fed LFD have significantly worsened 
glucose tolerance and adipose tissue insulin resistance than B6 controls.  This B6.SLE glucose 
intolerance occurs in the presence of a diabetogenic B cell environment which is characterized 
by the presence of an increased number of IgG-producing B cells and IgG depositions in the 
white adipose tissue as well as higher levels of circulating IgG.  The hyperglycemia and insulin 
resistance present in B6.SLE mice may contribute to CVD by causing increased expression of 
chemotactic factors and adhesion molecules by vascular endothelial cells and by causing ER 
stress-induced apoptosis in macrophages (20) Although it is clear that SLE patients and the 
B6.SLE mouse model suffer disproportionately from CVD (9, 199), the causes of this disparity 
have not been completely elucidated.   Insulin resistance has higher prevalence in the SLE 
population and it is conceivable that it could be a contributing factor in the high CVD burden in 
these patients.  Our current findings suggest potential mechanisms that give rise to metabolic 
disease in SLE patients and form the foundation for additional studies that could lead to greater 
understanding of the pathogenesis of SLE co-morbidities.  
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CHAPTER III 
THE EFFECT OF HIGH FAT DIET ON THE PATHOGENESIS OF LUPUS                   
IN B6.SLE MICE 
Introduction 
Systemic lupus erythematosus (SLE) is characterized by the production of autoantibodies 
against self-antigens such as, double stranded DNA (dsDNA) and phospholipids. Unfortunately, 
the etiology and environmental triggers for SLE remain largely unknown.  Therefore, it is 
necessary to complete studies of variables that increase personal risk for development and 
exacerbation of the progression of SLE and its comorbidities.   
A CDC Morbidity and Mortality Weekly Report published in 2002 showed that the SLE 
death rate increased by 33% between 1979 and 1998.  Although this expansion of the lupus 
patient population could have resulted from improved diagnostic techniques, it could also be due 
to an actual increase in the incidence of SLE and/or more severe disease secondary to 
environmental factors.  One environmental factor that has rapidly increased during this time 
period is obesity.  The epidemic of overweight and obesity is the preeminent health concern of 
the Western world and is associated with a constellation of comorbidities, including 
dyslipidemia, hypertension and insulin resistance.  In addition to these classical comorbidities, 
there is increasing evidence that obesity negatively impacts a wider spectrum of diseases such as 
cancer and inflammatory diseases.  Because SLE has been demonstrated to be exacerbated by 
high fat diet in both humans (37, 116)  and mouse models (5, 44, 98, 110, 143, 240) and recent 
studies have demonstrated that SLE alters insulin sensitivity, it is important to investigate how 
metabolism and autoimmunity are interlinked.   
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  Several studies have linked diet and obesity to exacerbation of autoimmunity.  When 
lupus prone NZB/W mice were fed a high-fat, lard-based diet, they had higher mortality rates 
and more severe glomerulonephritis than mice fed a low-fat diet (98), and a diet high in omega-3 
polyunsaturated fatty acids protected against disease (5, 77).  High fat diet also worsens disease 
in the MRL/lpr mouse model of lupus (143).  These effects are not limited to lupus: HFD feeding 
exacerbates other mouse models of disease colitis and experimental autoimmune 
encephalomyelitis secondary to diet-mediated changes to changes in the T lymphocyte 
compartment (226).  Furthermore, diet supplementation with omega-3 polyunsaturated fatty 
acids ameliorates disease in  humans with SLE (217). 
 Patients with lupus are nearly eight times more likely to die of renal disease than the 
general population  (14) and the majority of kidney disease burden consists of diffuse 
proliferative lupus nephritis and membranous lupus nephritis (132).  Lupus nephritis is instigated 
when anti-nuclear antibodies form immune complexes which deposit on the glomerular 
basement membrane.  This spurs the activation of a signaling cascade of chemokines and pro-
inflammatory cytokines which directly damage the glomerulus and indirectly cause damage 
through leukocyte recruitment (123, 245).  T cell infiltrates include Th1, Th2 and Th17 subtypes 
(132), and B cell infiltrates occupy the renal tubulointerstitium where they produce anti-nuclear 
antibodies (57).  SLE patients have higher circulating TH17 cell numbers and higher plasma 
levels of IL23 and IL-17 (229) and these results are mirrored in the MRL/lpr mouse model of 
lupus (106, 244).  Furthermore, IL-23R deficiency prevented anti-dsDNA antibody production 
and protected against the development of glomerulonephritis in this model (106, 244).   Kidney 
damage in both human and mouse studies was attributed in part to kidney infiltration by an IL-
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17-producing lymphocyte population that was enriched for CD4-CD8- double negative (DN) T 
cells that produce IL-17, IFN-γ, and TNF-α (46).   
Interestingly, HFD and obesity exacerbate disease in mouse models of colitis and 
multiple sclerosis through expansion and activation of the Th17 population (226) and it is 
possible that HFD influences the development of lupus nephritis in a mouse model of lupus 
through similar mechanisms. To test this hypothesis, we fed LFD or HFD to the B6.SLE mouse 
model of lupus, which was bred to have fully-penetrant glomerulonephritis (139) and measured 
parameters of renal function, morphology and inflammatory state.  Although significant 
worsening of these parameters was observed in B6.SLE mice relative to B6 controls, HFD-fed 
B6.SLE mice did not have a worsened kidney disease relative to their LFD-fed counterparts. 
Materials and Methods 
Mice.  B6.Sle.1.2.3 mice, hereafter referred to as B6.SLE mice, were a generous gift of Edward 
Wakeland (UTSW, Dallas, TX) and have been previously described (139).  C57BL/6 mice (B6) 
were originally purchased from Jackson Labs (Bar Harbor, ME), and were bred in the animal 
facility at Vanderbilt University Medical Center.  All procedures involving animal subjects 
received prior approval from the Vanderbilt University Institutional Animal Care and Use 
Committee.  
Diet. B6 and B6.SLE mice were co-housed after weaning and fed low fat diet (LFD, 10% Kcal 
from fat, D12450B, Research Diets, New Brunswick, NJ) or HFD (HFD, 45% Kcal from fat, 
D12451, Research Diets, New Brunswick, NJ) ad libitum. 
Flow Cytometry. Single-cell suspensions of kidney mononuclear cells were isolated as follows: 
kidneys were minced and digested for 20 minutes at 37° C with 1mg/ml collagenase in HBSS 
(Sigma, St. Louis, MO).  Digested kidney was passed through a 40 micron filter and 
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mononuclear cells were isolated from the interface of a 40%/60% Percoll gradient (GE 
Healthcare, Piscataway, NJ).  In order to minimize non-specific binding of flow antibodies, cells 
were blocked for 15 minutes at RT with a 1:200 dilution of Fc receptor block (BD Biosciences, 
San Diego, CA) in a FACS buffer consisting of 1X HBSS, 1% BSA, 4.1663 mM sodium 
bicarbonate and 3.0765 mM sodium azide.  The following fluorescently-labeled antibodies were 
diluted 1:200 in FACS buffer and incubated with the cells for 45 minutes at 4º C:  CD19-PECy7, 
B220-A450, TCRβ-PECy7, CD8-FITC and CD4-APCCy7 (BD Biosciences, San Diego, CA).  
The labeled cells were washed 3 times with FACS buffer and fixed overnight at 4º C in a 
solution of 2% paraformaldehyde in PBS.  Labeled cells were analyzed on a MACSquant seven-
color flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany) and data was analyzed 
with FCS Express 4 (De Novo Software, Los Angeles, CA). 
Real Time.  Kidney RNA was isolated using a RNeasy Mini Kit (Qiagen, Valencia, CA) and 
cDNA was synthesized using an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA).  The 
quantitation assays were completed using Taqman Gene Expression Master Mix (Applied 
Biosystems, Foster City, CA) and Taqman Probes for the specified genes according to 
manufacturer’s instructions.  Threshold Ct values were measured with SDS2.3 software (Applied 
Biosystems, Foster City, CA) and transcript levels measured using the 2
-ΔΔCt
 method.  18s was 
used as the reference gene and the LFD-fed B6 group was used as a comparator. 
Histology. Female mice were sacrificed after 26 weeks of HFD feeding and kidneys were 
removed, embedded in paraffin and stained with H&E.  Glomerulus size was measured in 4-5 
independent fields per slide using ImageJ software (National Institutes of Health, Bethesda, MD) 
and data was expressed as pixels per glomerulus. 
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Measurement of Serum Creatinine and Urine Protein. Male B6 and B6.SLE mice were fed 
HFD or LFD for 20 weeks.  Serum was collected and creatinine concentration was measured 
using a QuanticChrom creatinine assay kit (BioAssay Systems, Hayward, CA) according to 
manufacturer’s instructions.  Urine protein was measured in randomly sampled urine from study 
mice using Multistix 10SG urinalysis strip (Siemens, Malvern, PA).   
Statistics. Statistical significance for GTT data was calculated with a two-way ANOVA for 
repeated measures.  All other significance was calculated with a Student’s t test comparing mice 
within diet groups.  All calculations were completed with GraphPad Prism software (GraphPad 
Software, Inc., La Jolla, CA).  Unless otherwise noted, all data was expressed as mean +/- SEM. 
Results 
Glomerular Tuft Size is Not Influenced by High-Fat Diet Feeding.  We assessed glomerular 
morphology in order to determine whether HFD exacerbated kidney disease in B6.SLE mice. 
Overall, B6.SLE mice in both diet groups had focal to diffuse proliferative changes that 
consisted of increased cellularity composed of endothelial and mesangial cells, increased 
mesangial matrix, thickening of capillary walls and areas of necrosis (Figure 18).  Glomerular 
tuft size is correlated with renal injury and is increased in B6.SLE mice relative to B6 controls.  
Both HFD-fed and LFD-fed mice had equal glomerular tuft size indicating that diet does not 
influence this disease parameter. 
 Kidney mass was also measured in LFD- and HFD-fed B6 and B6.SLE mice (Figure 19).  
Total kidney mass was increased in HFD-fed B6.SLE mice relative to the B6 control group but 
there was no difference in kidney mass between the LFD-fed groups.  Additionally, there was a 
trend towards higher mass in the HFD-fed B6.SLE mice relative to their LFD-fed B6.SLE 
counterparts. 
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Figure 18.  Glomerular tuft size is increased in B6.SLE mice.  Female mice were sacrificed after 26 weeks of 
HFD feeding and kidneys were removed , embedded in paraffin and stained with H&E.  Glomerulus size was 
measured in 4-5 independent fields per slide and data was expressed as pixels per glomerulus. (n=4-5 per group.  
*p<0.05. 
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Figure 19. Kidney weight is increased in HFD-
fed B6.SLE mice. Female B6 and B6.SLE mice 
were fed HFD or LFD for 28 weeks.  Mice were 
sacrificed and kidneys were weighed.  Data is 
expressed as the total weight of both kidneys. n=4-6 
mice/group. *p<0.05.   
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Figure 20. Serum creatinine is not increaed in 
B6.SLE mice.  Male B6 and B6.SLE mice were 
fed HFD or LFD for 20 weeks.  Serum was 
collected and creatinine concentration was 
measured using the Jaffe picrate method. n=5-7 
mice/group. 
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Figure 21. Urine protein trends higher in HFD-fed B6.SLE mice.  Male B6 and B6.SLE mice were fed HFD 
or LFD for 20-28 weeks.  Urine was sampled from mice and applied to a Siemens  Multistix 10SG urinalysis 
strip.  Results are expressed as urine protein score, with higher numbers correlating with higher urine protein 
content. 
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Figure 22. The CD8+ T cell population is increased in B6.SLE mice.  Female B6 and B6.SLE mice were fed 
HFD or LFD for 28 weeks.  Mice were sacrificed and kidneys harvested.  Kidney mononuclear cells were 
isolated using a Percoll gradient and cells were stained for markers of B cells and T cells. n=4-6 mice/group. 
*p<0.05. 
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Kidney Function is Not Significantly Worse in B6.SLE Mice.  Serum creatinine and urine 
protein levels positively correlate with worsened kidney function.  There were no significant 
differences in serum creatinine between any groups (Figure 20), but there was a trend towards 
higher creatinine in HFD-fed B6.SLE mice.  There were also trends towards higher urine protein 
in B6.SLE relative to B6 controls, and trends towards higher urine protein in HFD-fed groups 
relative to their LFD-fed counterparts (Figure 21).  
 
HFD Does Not Significantly Influence Inflammation or the Immune Cell Compartment in 
B6.SLE mice.  The kidney mononuclear cell population was measured using flow cytometry 
(Figure 22).  There was a significant increase in the proportion of TCRβ+ T cells in B6.SLE 
groups which was accompanied by a relative decrease in kidney CD19+ B cells.  The CD8+ T 
cell population constituted most of the increase in renal T cells.  There was a significant increase 
 
Figure 23. There is increased renal expression of proinflammatory cytokine in B6.SLE mice. Female B6 
and B6.SLE mice were fed HFD or LFD for 28 weeks.  Mice were sacrificed and kidneys harvested.  Kidney 
RNA was isolated and expression of various cellular markers and cytokines was measured using quantitative 
real-time pcr. n=4-6 mice/group. *p<0.05.   
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in expression of the pro-inflammatory cytokines TNF-α, IL-12b, IL-6 and TGFβ in HFD-fed 
B6.SLE mice and trends towards higher expression of these cytokines in the LFD-fed B6.SLE 
mice, indicating a trend towards higher inflammation in the kidneys of SLE-prone mice (Figure 
23).  
Discussion 
We hypothesized that HFD would exacerbate kidney disease in the B6.SLE mouse model of 
lupus.  Several prior studies have indicated that HFD feeding exacerbates disease in mouse 
models (5, 44, 98, 110, 143, 240) and in humans (37, 116) and also worsened mouse models of 
EAE and colitis.  To test this hypothesis, we fed HFD to lupus-prone B6.SLE mice and measured 
kidney morphology, renal function, kidney cellular content and renal inflammation.  Although 
B6.SLE mice had significantly worsened kidney inflammation and more T cell infiltrate than B6 
controls, these parameters were nearly equal between HFD-fed B6.SLE and LFD-fed B6.SLE 
mice. 
 There are several factors that could have contributed to the lack of diet response in HFD-
fed B6.SLE mice.  This is the first study of dietary effects on lupus nephritis in the B6.SLE 
mouse model.  Previous studies primarily focused on the NZB/NZW F1 or MRL/lpr/lpr models 
which may be more susceptible to HFD-feeding than B6.SLE mice.  Furthermore, although the 
percentage of lard by weight was similar between the diets used in our studies and previous 
studies, it is possible that differences in other macronutrients and micronutrients (not described 
in the original publications) influenced disease levels.  The length of our experiment was roughly 
equivalent to those of previous experiments, but it is possible that differences may be observed if 
the experimental duration was extended in this mouse model.  Furthermore, a diet higher in fat 
might be necessary to elicit changes in B6.SLE mice.  One study showed that lupus-prone mice 
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fed a diet high in omega 3 polyunsaturated fatty acids had less severe disease than mice fed a 
lard-based diet.  It is important to repeat these studies in B6.SLE to determine whether 
polyunsaturated fatty acids could also ameliorate disease in this strain. 
 In conclusion, B6.SLE mice fed a high-fat diet (45% Kcal from fat) did not have 
significantly worsened kidney disease compared to LFD-fed B6.SLE mice as measured by 
kidney morphology, renal function, kidney cellular content and renal inflammation.  Although 
the 45% Kcal from fat diet did not exacerbate disease, it will be necessary to repeat this 
experiment with a higher-fat diet (60% Kcal from fat) or a diet high in omega 3 polyunsaturated 
fatty acids in order to determine whether these diets worsen or ameliorate disease. 
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
Comparison of Metabolic Disease in the B6.SLE Strain to Humans with SLE 
 Humans suffering from SLE are at increased risk of developing insulin resistance and 
other components of the metabolic syndrome.  Although SLE patients and B6.SLE mice both 
have similar adiposity to healthy controls (10, 38, 116),  the manifestation of metabolic disease 
in B6.SLE mice differs from  SLE patients in several ways.  SLE patients have elevated fasting 
insulin levels whereas insulin levels in B6.SLE mice are equivalent to controls, and both SLE 
patients and B6.SLE mice maintain normoglycemia in the setting of lupus (37, 38, 210). Most 
studies of human SLE patients showed that there was no increase in total serum cholesterol (38, 
116, 167, 189, 210) and at least three separate studies showed that serum triglycerides were 
increased in the SLE patient population (37, 38, 116).  In contrast, B6.SLE mice had 
significantly lower total serum cholesterol and triglyceride than B6 controls in both diet groups.  
All known studies of metabolic disease in SLE patients have been completed in females, owing 
to the relative scarcity of male SLE patients.  The studies in Chapter 2 included both male and 
female B6.SLE mice.  We found that LFD-fed male B6.SLE mice and HFD-fed female B6.SLE 
mice had increased glucose intolerance that was independent of body composition.  Male mice 
and humans tend to be at higher risk of developing insulin resistance (122), and it is therefore 
possible that male SLE patients would have more severe insulin resistance than females with 
SLE.   
 The mechanisms that give rise to insulin resistance in the setting of human SLE have not 
been completely elucidated, although adiposity (116) and corticosteroid treatment (116, 167, 
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210) have been ruled out as contributing factors.  The level of circulating IL-18, a pro-
inflammatory cytokine which promotes the activation of T cells and NK cells, positively 
correlates with insulin resistance in SLE patients (85) and the general population (208) and may 
be a potential therapeutic and investigative target for SLE-associated insulin resistance.  IL-18 
levels were not measured in B6.SLE mice in our studies and it is not clear whether this cytokine 
contributes to insulin resistance and glucose intolerance in this strain.  Another factor that may 
link SLE and insulin resistance is BAFF, which is described in the mechanism section below. 
 In conclusion, the B6.SLE strain mirrors some aspects of insulin resistance in humans 
with SLE.  Both adipose tissue insulin resistance and glucose intolerance in B6.SLE mice occur 
in a body composition-independent manner, while SLE patients are hyperinsulinemic in the 
setting of normal BMI.  Other aspects of metabolic disease in SLE patients, including 
hypertriglyceridemia, hyperinsulinemia and normocholesterolemia, and are not replicated in the 
B6.SLE model.  The metabolic phenotype of the lupus-prone NZBWF1 strain, described by 
Ryan et al., has many similarities to the human population; however, it is unclear whether lupus 
disease contributed to metabolic disease in this model. The study of Ryan et al. will be compared 
to our study in the following section. 
Comparison of Metabolic Disease in B6.SLE Strain to the NZBWF1 STRAIN 
 To our knowledge, there is only other study of IR and glucose intolerance in a mouse 
model of SLE.  In that study, Ryan et al. examined glucose homeostasis in the NZB/W F1strain, 
a progenitor of the B6.SLE strain (185).  Similar to the results observed in B6.SLE mice, the 
NZB/W F1 strain had increased glucose intolerance in the setting of a low-fat, normal chow diet.  
Additionally, NZB/W F1 mice had increased mean arterial pressure relative to controls which 
correlates with the increased systolic blood pressure observed in LFD-fed B6.SLE mice (Figure 
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24). In contrast, Ryan et al. observed hyperleptinemia, hyperinsulinemia, and increased 
macrophage content in the white adipose tissue.  This differs from LFD-fed B6.SLE mice, which 
had similar fasting insulin, fasting leptin and adipose tissue macrophage levels to B6 controls.  
Furthermore, there was increased hepatic lipid accumulation in NZB/W F1 mice, which was in 
contrast to the significantly reduced triglyceride content observed in the B6.SLE strain.  
 
 The discrepancies between our results and those of Ryan et al. were somewhat 
unexpected, as the NZB/W F1 strain is a progenitor of the B6.SLE strain.  The NZB/W F1 strain 
is the first filial offspring (F1) of a mating between a New Zealand Black (NZB) female mouse 
and New Zealand White (NZW) male mouse.  The offspring develop fully-penetrant 
glomerulonephritis which develops earlier and more severely in females (104).  A series of 
crosses between NZB/W F1 mice, NZW mice and their offspring resulted in the generation of 
the New Zealand Mixed (NZM) 2410 strain, which also invariably develops fulminant lupus.  
Lupus susceptibility loci were genetically mapped in the NZM2410 strain (139) and these loci 
were backcrossed onto the C57BL/6 background to generate the B6.SLE strain (141).  As in the 
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Figure 24 LFD-fed male B6.SLE mice have increased systolic blood pressure. Male B6 and B6.SLE mice 
were fed HFD or LFD for 18 weeks.  Study mice were preconditioned and blood pressure was measured by tail 
cuffing.  N=3-6/group.  *p<0.05 by Student’s t test. 
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progenitor strains, both males and females in this strain suffer from fully-penetrant lupus and 
females tend to develop clinically apparent glomerulonephritis at a younger age.  Lupus 
susceptibility in the NZB/W F1 and B6.SLE mouse models relies on multiple genes and both 
models mirror the polygenic nature of most forms of human SLE.  However, one strength of the 
congenic B6.SLE strain relative to the NZB/W F1 strain is that their B6 background makes it 
possible to isolate the effects of the lupus susceptibility loci through the B6 controls.  Only the 
minimal genetic intervals necessary to confer glomerulonephritis were backcrossed onto the 
C57BL/6 background in the B6.SLE strain, lessening the risk of disrupting genes necessary for 
normal glucose homeostasis in the C57BL/6 strain.  However, the gene encoding the leptin 
receptor is present on the SLE2 locus on chromosome 3 and was carried over to the C57BL/6 
background when the congenic B6.SLE strain was generated.  LFD-fed B6.SLE mice had similar 
fasting leptin levels to B6 controls and HFD-fed B6.SLE mice had significantly lower fasting 
leptin than controls (Figure 6).  This data provides preliminary evidence that normal leptin 
signaling is not impaired in B6.SLE mice, but no formal assessment of leptin receptor function 
was completed in these studies.   Both the NZB parental strain or NZW parental strain may be 
used as controls when working with NZB/W F1 mice.    In the studies of Ryan et al., the authors 
reported results from the NZW strain, but not the NZB parental strain.  NZW mice frequently 
develop anti-ssDNA antibodies but their autoimmune disease is not clinically apparent at 36 
weeks of age (104).  NZB mice have more consequential disease than the NZW strain and 
produce anti-nuclear antibodies which can give rise to mild glomerulonephritis that becomes 
clinically apparent well after 36 weeks of age (83).  Although body composition is comparable 
between NZB and NZW mice at 16 weeks of age (174), the body composition of these strains at 
36 weeks of age has not been reported.  Therefore, it is possible that levels of adiposity and 
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metabolic disease in NZB mice, but not NZW mice, are equivalent to those of the NZB/W F1 
strain at 36 weeks of age.   Further studies comparing NZB/W F1 mice to the NZB parental 
strain should be completed in order to determine whether glucose intolerance is secondary to the 
autoimmune disease present in NZBWF1 mice or SLE-independent accumulation of adipose 
tissue.  
 The studies of Ryan et al. focused on LFD-fed 36-week-old females, whereas we 
examined both 25-week-old male and 35-week-old female B6.SLE mice.  Although we observed 
glucose intolerance in low-fat diet fed male B6.SLE mice relative to controls, no exacerbation in 
glucose tolerance was observed in LFD-fed female B6.SLE mice.  However, glucose intolerance 
was significantly worsened in HFD-fed female B6.SLE mice relative to controls.  Since female 
mice in our study were at a similar age to female mice in the Ryan study (35 weeks and 36 
weeks, respectively), we expected LFD-fed female B6.SLE mice and NZB/W F1 mice to have 
equally high glucose intolerance.  However, it is difficult to compare the results of Ryan et al. to 
ours, as NZB/W F1 body composition was radically different than that observed in B6.SLE 
mice.  NZB/W F1 mice were over 11 grams heavier than controls and had twice as much visceral 
adipose tissue. Additionally, the total body weight and visceral adipose tissue depot mass were 
significantly higher than that observed in B6.SLE mice at the same age.  LFD-fed B6.SLE mice 
weighed an average of 27 grams (versus 45.7 grams in NZB/W F1 mice) and had a total of 3 
grams body fat (versus 5 grams of fat in the viscera alone in NZB/W F1 mice).  These large 
differences in weight and adiposity complicate the interpretation of the results of Ryan et al.  The 
overall phenotype in NZB/W F1 mice is more consistent with phenotype observed in obese 
C57BL/6 mice.   Like obese mice, NZB/W F1 mice have hyperinsulinemia, hyperleptinemia, 
increased glucose intolerance, increased adipose tissue macrophage infiltration and increased 
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hepatosteatosis.  In contrast, B6.SLE mice have similar or lower adiposity and significantly 
higher lean body mass than B6 controls in both genders and diet groups.  Unlike obese mice, 
glucose intolerance and adipose tissue insulin resistance is not accompanied by 
hyperinsulinemia, hyperleptinemia, hepatic insulin resistance or hepatosteatosis. Therefore, we 
hypothesize that the mechanisms which contribute to the severe glucose intolerance observed in 
B6.SLE mice are distinct from those that give rise to glucose intolerance in obese mice or 
NZB/w F1 mice.  Furthermore, since the NZB/W F1 strain is merely a hybrid of the parental 
NZB and NZW strains and parental genes unrelated to lupus pathogenesis are conferred to their 
offspring, it is possible that the metabolic results reported in Ryan et al. are not directly related to 
the pathogenesis of lupus.  Additionally, the weight gain and adiposity observed in NZB/W F1 
mice was likely exacerbated by the significantly lessened locomotor activity in this strain relative 
to the NZW controls.   
 In conclusion, we assert that the B6.SLE strain is more suitable than the NZB/W F1 
strain as a model SLE-associated insulin resistance in humans.  Although the manifestation of 
metabolic disease in the B6.SLE model varies from that of humans in regards to fasting insulin 
levels and serum triglyceride levels, both SLE patients and B6.SLE mice suffer disruption of 
glucose homeostasis in the setting of unchanged body composition. Although Ryan et al. 
observed significant hyperinsulinemia and glucose intolerance in the NZB/W F1 model, it is 
unclear whether metabolic changes are secondary to increased adiposity or lupus disease.  
Furthermore, the B6.SLE mouse is a more precise model than the NZB/W F1 strain, as only the 
lupus susceptibility loci were backcrossed onto the C57BL/6 background.  Since NZB/W F1 
mice are a hybrid of two different parental strains, it is difficult to design appropriate controls 
which isolate the influence of SLE susceptibility on metabolism from the general metabolic 
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characteristics of the parental strains.  Therefore, future studies in this area should focus on the 
B6.SLE strain in order to gain a better understanding of the pathogenesis of metabolic disease in 
the context of SLE. 
Proposed Mechanism 
In chapter 2, we showed increased glucose intolerance and adipose tissue insulin 
resistance in B6.SLE mice.  Interestingly, this phenotype was observed in the context of LFD-
feeding and there was no significant difference in adiposity between B6.SLE and control B6 
mice.  To our knowledge, this is the first study that has shown spontaneous glucose intolerance 
and adipose tissue insulin resistance in LFD-fed mice which were not associated with changes in 
adiposity or deliberate modification of metabolism-related genes.  Since there were no changes 
in body composition that would predispose mice to glucose intolerance, it is possible that SLE-
associated immune changes are a key driver of dysfunctional glucose homeostasis.  The influx of 
immune cells into the adipose tissue of B6.SLE mice differs slightly from that observed in the 
adipose tissue of obese mice.  CD8
+
 T cell and macrophage proportions are increased in the 
adipose tissue of obese mice; although we observed increased CD8+ T cell proportions in 
B6.SLE mice, we did not observe a concomitant increase in macrophages (151, 225).  Winer et 
al. showed an increase IgG deposition and IgG+ B cell content in the adipose tissue of HFD-fed 
mice, a phenomenon that was also present in B6.SLE mice (Figure 10). 
Presumably, the adaptive immune system is responding to adipose tissue antigens which 
are revealed as part of obesity or the SLE disease process, but there is only tenuous evidence to 
support this hypothesis.  There are no data showing that the adipose antigenic targets of the 
immune system are conserved between obesity-associated insulin resistance and SLE-associated 
insulin resistance, or even that targets are shared among all mice with obesity-associated insulin 
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resistance.  However, the identification of adipose tissue target antigens would be a high-impact 
finding that could lead the development of therapeutics that could be used to treat type 2 diabetes 
in humans.  Furthermore, it is possible that characterization of the adipose targets in SLE-
associated insulin resistance could lead to the identification of antigen targets which would be 
applicable in obesity. 
Lupus is characterized by the generation of antibodies against a wide variety of 
intracellular antigens, including dsDNA, histone, cardiolipin, and ribosomal proteins (148).  
These intracellular antigens become exposed during the process of apoptosis (215).  Defects in 
the pro-apoptotic pathway components lpr and Bim have been observed in the SLE patient 
population and mice bearing these mutations suffer from early and severe SLE-like disease (87).  
Furthermore, clearance of apoptotic cells is impaired in both lupus patients and the 
NZBNZW(F1) and MRL/lpr mouse models of lupus (81, 108, 146).  The abnormal presentation 
of intracellular self-antigens, paired with defects in the negative selection of self-reactive 
lymphocytes (17),  leads to the production of the anti-self-antibodies that are a hallmark of SLE. 
Adipocyte apoptosis and necrosis have been observed in obese mice and humans and is 
associated with adipose tissue leukocyte infiltration and insulin resistance.  HFD-fed mice 
lacking the pro-apoptotic factor Bid are protected against glucose intolerance and insulin 
resistance and have reduced adipose tissue macrophage infiltration (6).  Crown-like structures, a 
key histological feature of obese adipose tissue that consists of leukocyte infiltrate, surround 
these dead or dying adipocytes and only 20% of baseline adipocytes remain intact after 20 weeks 
of HFD feeding (39, 200).  A potential instigating factor for adipocyte death in obesity is adipose 
tissue hypoxia, which can lead to either necrosis or apoptosis in various cell types and tissues 
(23, 117) 
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 Adipose tissue oxygenation was shown to be reduced in the adipose tissue of obese 
C57BL/6 mice and this reduction was correlated with increased expression of  hypoxia-inducible 
factors 1α and 2α (HIF-1α and HIF-2α) (173).  Hypoxia caused increased expression of TNF-α, 
IL-1, and IL-6 (239), suppressed expression of the insulin-sensitizing adipokine adiponectin, and 
induced apoptosis and necrosis in the 3T3-L1 cell line. HIF-1α appears to be a critical regulator 
of the adipose tissue dysfunction observed in obesity.  A transgenic mouse with constitutively 
overexpressed HIF-1α suffers from worsened glucose tolerance and insulin resistance which was 
associated with increased macrophage infiltration into the white adipose tissue (78).  
Furthermore, patients suffering from sleep apnea, a breathing disorder which results in 
intermittent  periods of hypoxia,  are predisposed to developing systemic insulin resistance (90, 
196).    
 The generation of an immune response to self-antigen necessitates the abnormal 
presentation of antigen and an escape from the normal processes of peripheral tolerance.  
Although the process of apoptosis in the adipose tissue of obese mice could unmask adipocyte 
antigens, it is not clear why peripheral tolerance would be impaired in obesity.  One factor which 
plays a key role in the maintenance of central and peripheral tolerance is B cell-activating factor 
(BAFF).  Overexpression of BAFF has been observed in mouse models of SLE and SLE patients 
and has been implicated in the survival of autoreactive B cells.  Interestingly, BAFF is secreted 
by adipocytes (4, 99) and the circulating levels of BAFF are increased in the context of obesity 
(80).  The presence of BAFF, paired with increased apoptosis of adipocytes, could be sufficient 
to generate an autoreactive immune response to adipose tissue antigens.   
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The experiments in Chapter 2 were not designed to assess the relative contributions of cellular 
immunity factors (e.g. a break in B cell or T cell tolerance to self-antigen) and tissue factors (e.g.  
abnormal exposure of self-antigen by  adipocytes) to the development of glucose intolerance and 
adipose tissue insulin resistance in B6.SLE mice.  However, a pilot study completed with 
B6.SLE radiochimeras shows that transplant of bone marrow from B6.SLE mice into B6 
recipients is sufficient to cause glucose intolerance in recipient mice (Figure 25).  In this 
experiment, bone marrow was harvested from 6 week-old male B6 or B6.SLE mice and was 
transferred into lethally-irradiated 6 week-old B6 mice.  Previous studies by our laboratory 
showed that transfer of B6.SLE bone marrow was sufficient to induce autoimmunity and 
accelerated atherosclerosis in recipient mice (199). Transplanted mice were rested for 2 weeks 
randomly assigned to a LFD (10% Kcal from fat) or HFD (45% Kcal from fat) diet group.  After 
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Figure 25. Glucose tolerance in B6.SLE radiochimeras. Six-week-old lethally irradiated B6 mice received a 
bone marrow transplant from a six-week-old B6 or B6.SLE donor.  Recipient mice were rested for two weeks  
before being assigned to LFD or HFD groups.  After 10 weeks of feeding, a glucose tolerance test was 
completed.  After 5-6 hours of fasting, mice were injected with 1.25 g glucose per kg body weight and blood 
glucose was measured using a One Touch Ultra glucometer.  n=9-10 mice/group. Data are expressed as change 
in blood glucose from baseline versus time.  *p<0.05 between LFD-fed B6.SLE and B6 mice via two-way 
ANOVA . 
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10 weeks of feeding, glucose tolerance was measured as described in Chapter 2.  As seen in 
 
Figure 25, LFD-fed B6 mice that received B6.SLE bone marrow had significantly worsened but 
relatively mild glucose intolerance than those that had received B6 bone marrow.  There was also 
a trend towards higher glucose intolerance in HFD-fed B6 mice.  However, B6.SLE glucose 
tolerance in both diet groups was equal to or lower than B6 controls after 15 and 20 weeks of 
feeding (data not shown).  This suggests that hematopoietic cells are sufficient to cause mild 
glucose intolerance after 10 weeks of feeding, but that lupus-related genetic susceptibility must 
be present in tissues in order to maintain worsened glucose tolerance. Since the contribution of 
tissue-specific factors was not assessed in this experiment, future experiments should also 
include B6.SLE recipients in order to address this question. 
 
 
 
Figure 26. Proposed pathogenic mechanism for B6.SLE-associated glucose intolerance. 
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The collective results from our studies and from the work of other laboratories form the 
basis of the following proposed mechanism (Figure 26).  Adipose tissue antigens become 
unmasked and are abnormally presented to the cells of the adaptive immune system in B6.SLE 
mice.  Adipose antigen-reactive T and B cells escape the mechanisms of peripheral tolerance that 
normally prune autoreactive lymphocytes, and CD8+ T cells infiltrate the adipose tissue and 
modulate the activity of B cells to produce adipose tissue reactive IgG.  These antibodies bind to 
adipocytes and cause damage through engagement of the adaptive and innate immune system.  
Finally, direct attack of adipocytes and the secretion of pro-inflammatory cytokines causes 
insulin resistance resulting in glucose intolerance. 
Future Directions 
 Several components of the proposed model remain to be tested experimentally.  The most 
important of these components is the contribution of IgG to the pathogenesis of adipose tissue 
insulin resistance and glucose intolerance.  As noted above, Winer et al. showed that passive 
immunization with IgG from obese mice was sufficient to induce insulin resistance in recipient 
mice.  In order to determine the contribution of IgG to glucose intolerance in the B6.SLE strain, 
we will harvest IgG from the serum of LFD-fed B6.SLE and B6 mice, and these antibodies will 
be used to passively immunize recipient B6 mice.  Glucose tolerance tests and adipose tissue 
insulin signaling will be used to assess the metabolic function in the passively immunized mice.  
If passive immunization is found to cause glucose intolerance and insulin resistance, we will 
attempt to determine the target antigens of these antibodies.  Emerging proteomic technology 
may facilitate the description of the putative adipose tissue targets of antibodies generated in the 
setting of SLE.  One approach for antigen discovery would be “antigen panning,” in which 
adipose tissue lysates from LFD-fed B6.SLE mice would be applied to a 2D electrophoresis gel.  
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Antibody from obese and SLE-prone mice would be applied to the 2D blot and antibody-tagged 
proteins would be identified using mass spectrophotometry.  Such an approach could identify 
adipose tissue antigen targets in B6.SLE-prone mice that may provide clues about the antigen 
targets of IgG in the setting of obesity.   
 It is also important to examine the role of BAFF in the pathogenesis of glucose 
intolerance and insulin resistance in the B6.SLE strain.  BAFF is a cytokine that can promote the 
survival of autoreactive B cells and has been found to be elevated in the circulation of SLE 
patients and SLE-prone mice (35).  Additionally, serum BAFF levels are associated with 
increased insulin resistance in obese mice and adipocytes have been shown to produce 
significant amounts of BAFF and to express the BAFF receptor (80).  Therefore, BAFF could be 
a factor that links the break in tolerance of B cells to the disruption of glucose homeostasis in 
B6.SLE mice.  Furthermore, it is possible that adipocytes produce the majority of BAFF in the 
setting of SLE.  Serum BAFF levels were significantly increased in B6.SLE mice (Figure 12), 
but it is not clear whether this cytokine contributes to glucose intolerance.  To address this 
question, we will inhibit BAFF activity through the use of neutralizing antibodies against BAFF 
and the BAFF receptor and will use recombinant BAFF to determine whether BAFF excess 
exacerbates metabolic disease in B6.SLE mice.  Additionally, we will use conditional BAFF and 
BAFF receptor knockout mice to specifically ablate expression of BAFF and BAFF receptor in 
adipocytes to determine whether BAFF signaling is necessary to induce glucose intolerance and 
adipose tissue insulin resistance in the B6.SLE model.  
 An additional future investigational target is the cytokine IL-18.  IL-18 is produced by 
macrophages and dendritic cells and affects the function of NK cells and T cells (208).  IL-18 
levels have been shown to be elevated in the settings of SLE and obesity (228, 231) and IL-18 
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levels positively correlate with metabolic syndrome in SLE patients (209).  Like BAFF, IL-18 is 
a potential link between autoimmunity and glucose intolerance in the B6.SLE strain.  Currently, 
it is not known whether IL-18 levels are increased in B6.SLE mice.  It will be necessary to 
complete IL-18 ELISAs in order to determine whether levels are abnormal in B6.SLE mice.  
Furthermore, IL-18 neutralizing antibodies, recombinant IL-18 and conditional IL-18 knockouts 
can be used to determine whether this cytokine contributes to glucose intolerance in B6.SLE 
mice. 
 In conclusion, we described glucose intolerance and adipose tissue insulin resistance in 
the B6.SLE mouse model of SLE that was not associated with increased adiposity.  Although 
these findings are novel in the B6.SLE strain, we were not able to determine the mechanistic 
basis of these metabolic changes.  Several pieces of data, including increased proportions of 
IgG+ B cells and CD8+ T cells in the SVF of B6.SLE mice (Figures 9 and 10) and increased 
levels of serum BAFF in B6.SLE mice (Figure 12) offer tantalizing clues about the pathogenic 
mechanisms that disrupt normal glucose homeostasis in B6.SLE mice.  The research directions 
described above could lead to the characterization of the factors that contribute to insulin 
resistance in the B6.SLE model and the SLE patient population. 
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SUMMARY AND CONCLUDING REMARKS 
 In this work we have shown for the first time that the B6.SLE mouse model of lupus is 
predisposed to the development of white adipose tissue insulin resistance and glucose 
intolerance.   These impairments in glucose homeostasis are independent of body composition 
and occur in the setting of a diabetogenic B cell phenotype which is similar to that observed in 
diet-induced obesity models of insulin resistance.  We showed that kidney disease in B6.SLE 
mice was characterized by glomerular tuft hypertrophy, increased infiltration by CD8
+
 T cells 
and increased renal tissue expression of pro-inflammatory cytokines in which was equally severe 
in  LFD-fed and HFD-fed SLE mice. 
 Overall, this body of work shows that the B6.SLE strain is a suitable mouse model of the 
insulin resistance observed in the SLE patient population.  Although HFD feeding did not 
exacerbate renal disease in B6.SLE mice, it is possible that other dietary factors such as vitamins 
could impact pathogenesis of the disease.  The studies described in this dissertation form a strong 
foundation for future investigations into the mechanisms by which autoimmunity can affect 
metabolism and by which metabolism can impact the pathogenesis of autoimmune disease. 
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